

# **Exhibit 52**

Page 1

1                   IN THE UNITED STATES DISTRICT COURT  
2                   FOR THE DISTRICT OF NEW JERSEY

3  
4                   \_\_\_\_\_  
5                   ) IN RE JOHNSON & JOHNSON )  
6                   TALCUM POWDER PRODUCTS ) MDL NO. 16-2738 (MAS)(RLS)  
7                   MARKETING SALES PRACTICES, )  
8                   AND PRODUCTS LIABILITY )  
9                   LITIGATION )  
10                  \_\_\_\_\_  
11  
12

13                  DEPOSITION OF REBECCA SMITH-BINDMAN, M.D.  
14                  San Francisco, California  
15                  Wednesday, March 20, 2024  
16                  Volume I  
17  
18  
19  
20

21                  Reported by:  
22                  CATHERINE A. NOLASCO, RMR, CRR, BS  
23                  CSR No. 8239  
24                  Job No. 6498236  
25                  PAGES 1 - 215

1 November 2023 -- your expert report? 2 THE WITNESS: I was just given the 21. 3 MR. HEGARTY: Twenty-one. Okay. Let me -- 4 let's go off the record quick. That's my fault. 5 (Discussion Off the Record.) 6 (Exhibit 2 was marked for identification by 7 the court reporter.) 8 MR. HEGARTY: Okay. We are back on the 9 record. 10 I had marked previously, as Exhibit No. 2, 11 Dr. Smith-Bindman -- Smith-Bindman's 2021 amended 12 report. I meant to have marked, as Exhibit No. 2, her 13 November 23rd, 2023, second amended report. 14 Q And is, now, Exhibit No. 2 your November 23rd, 15 2023, second amended report? 16 A It is. 17 Q And can you look through it and does it appear 18 to be what you believe to be the entirety of your 19 November 23rd, 2023, second amended report? 20 A Yes. 21 Q Okay. Thank you. 22 I'm going to mark next, as -- I'll tell you 23 which one -- as Exhibit No. 3, your 2022 paper, 24 "Association Between the Frequent Use of Perineal Talcum 25 Powder Products and Ovarian Cancer: a" systemic --	Page 18 1 then. 2 Q You generated a version of the same meta 3 analysis you published in 2022 as part of your work as 4 an expert for Plaintiffs in the talc litigation, 5 correct? 6 A I would also say that differently. I -- I did 7 a review, and then the Woolen review was a new review 8 from scratch. 9 Q You initially set out the review along the 10 lines of what was published that you said started from 11 scratch in the reports you prepared for the MDL dated 12 November 18, 2018, correct? 13 MS. O'DELL: Object- -- 14 THE WITNESS: Yes. 15 BY MR. HEGARTY: 16 Q You did not start the review that you describe 17 in your November 2018 report prior to being contacted by 18 Plaintiffs' counsel in this litigation, correct? 19 A Correct. 20 Q You subsequently set out your meta analysis 21 that you had done as part of your work on the talc 22 litigation in your second amended report of July 2021, 23 correct? 24 A I don't understand the question. 25 Q You continued to talk about the meta analysis
Page 19 1 "Systematic Review and Meta-analysis." 2 I'm going to mark that as Exhibit No. 3. 3 (Exhibit 3 was marked for identification by 4 the court reporter.) 5 MS. O'DELL: I'm just going to put that in the 6 basket since she's going to be looking at that one. 7 BY MR. HEGARTY: 8 Q And do you have a copy of Exhibit No. 3, 9 Dr. Smith-Bindman? 10 A Yes. 11 Q What journal was Exhibit No. 3 published in? 12 A JGIM, Journal of General Internal Medicine. 13 Q Had you ever published in that journal before? 14 A I think so. 15 Q Your 2022 -- well, first of all, I'm going to 16 call it -- I'll refer to it as the Woolen paper; is that 17 fair? 18 A Yes. 19 Q Your 2022 Woolen paper was based on a meta 20 analysis that you started for litigation, correct? 21 A I -- 22 MS. O'DELL: Object to form. 23 THE WITNESS: I wouldn't characterize it that 24 way. 25 MR. HEGARTY: Let me ask in a different way,	Page 21 1 you had done as part of your work in the talc litigation 2 in your first amended report -- 3 A Yes. 4 Q -- correct? 5 A Yes. 6 Q And in your most recent amended report, now 7 you talk about the Woolen 2022 paper, correct? 8 A That's correct. 9 Q And is it -- are you telling me that none of 10 the work that went into the Woolen paper and getting it 11 published was done as part of your work in any of the 12 amended reports that you prepared? 13 A That's correct. 14 Q You did not include -- let me ask a different 15 way. 16 Was any of the work that went into the meta 17 analysis that eventually became the 2022 Woolen report 18 invoiced to Plaintiffs' counsel in this litigation? 19 A It is correct that none of that work was paid 20 for by Plaintiff counsel. 21 Q Was any percentage of thought or initiation or 22 the genesis of the 2022 Woolen paper part of your work 23 in this litigation? 24 MS. O'DELL: Object to the form. 25 THE WITNESS: The idea for doing a systematic

<p style="text-align: right;">Page 22</p> <p>1 review on the topic grew out of my work as an expert, 2 but the actual work on the new systematic review led by 3 Woolen was deliberately and very explicitly new work led 4 by Dr. Woolen. I helped guide him, and I was a 5 participant, but it was very deliberately started from 6 scratch without any of the insights that I may have 7 learned from the prior review.</p> <p>8 BY MR. HEGARTY:</p> <p>9 Q Is it fair to say, though, that you would not 10 have done the meta analysis that was published as of 11 2022 Woolen paper if you had not been contacted by 12 Plaintiffs' counsel to work on the talc litigation?</p> <p>13 A I would agree that this was a new area 14 entirely for me. I didn't know anything about this 15 topic area before I was approached to be an expert. 16 Once I learned about the topic, then I became interested 17 in -- in wanting to produce this work in the scientific 18 literature. So in terms of a topic area, this was 19 entirely new to me from the expert witness work that I 20 did.</p> <p>21 Q Would you agree that if you had never been 22 contacted by Plaintiffs' counsel to work on this case, 23 you would not have prepared the 2022 Woolen meta 24 analysis?</p> <p>25 MS. O'DELL: Object to the form. Speculation.</p>	<p style="text-align: right;">Page 24</p> <p>1 O'Brien paper --</p> <p>2 THE WITNESS: I would need to see it.</p> <p>3 MR. HEGARTY: We have a copy of the O'Brien 4 paper in -- it should be --</p> <p>5 MS. O'DELL: Do you want to see that?</p> <p>6 THE WITNESS: I don't mind.</p> <p>7 MR. HEGARTY: Yeah, it's right here.</p> <p>8 And we'll go ahead and mark that as Exhibit 9 No. 4. I think we're on Exhibit No. 4, aren't we?</p> <p>10 MS. FLAGEOLLET: Yep.</p> <p>11 (Exhibit 4 was marked for identification by 12 the court reporter.)</p> <p>13 BY MR. HEGARTY:</p> <p>14 Q So I've had marked, as Exhibit No. 4, the 2020 15 O'Brien study that I had just referenced in my question.</p> <p>16 Do you have a copy of that paper in front of 17 you, Doctor?</p> <p>18 A I do.</p> <p>19 Q If you look at the very first page in the 20 abstract, it -- when it talks about exposure, it looks 21 at ever long-term greater than 20 -- greater than or 22 equal to 20 years and frequent greater than or equal to 23 once per week; is that correct?</p> <p>24 A I do see that in the abstract. I'm just 25 checking the -- yes.</p>
<p style="text-align: right;">Page 23</p> <p>1 THE WITNESS: I have contributed or led a 2 number of systematic reviews, probably a half dozen or 3 so. I went down this area of investigation because I 4 was contacted about this, but whether or not I could 5 have gotten to that same place, I would have no idea.</p> <p>6 MR. HEGARTY: Let me see if you can answer it 7 this way.</p> <p>8 Q Would you agree that it's more likely than not 9 you would not have done the -- the meta analysis set out 10 in the 2022 Woolen paper if you had never been contacted 11 about serving as an expert witness for Plaintiffs in the 12 talc litigation?</p> <p>13 A I think that's probably true.</p> <p>14 Q Now, with regard to the -- the manner in which 15 you define frequency in your 2022 Woolen paper, the 2022 16 [sic] O'Brien study of the four cohorts looked at 17 frequency of use as well, correct?</p> <p>18 A In a limited number of those papers, it did 19 look at frequency of use. I think there are four 20 papers, and I think they were able to look at frequency 21 in two of them.</p> <p>22 Q The 2022 [sic] O'Brien study defined frequency 23 as greater or equal to once a week.</p> <p>24 Does that sound right to you?</p> <p>25 MS. O'DELL: And if you need to see the</p>	<p style="text-align: right;">Page 25</p> <p>1 Q Thank you.</p> <p>2 The 2020 O'Brien study, as you found -- or let 3 me start over again.</p> <p>4 The 2022 [sic] O'Brien study, as you even 5 state in the 2020 Woolen paper, found as its main 6 conclusion that there was no statistically significant 7 association between genital talc use and ovarian cancer, 8 correct?</p> <p>9 MS. O'DELL: Where -- where are you reading, 10 please? Just --</p> <p>11 MR. HEGARTY: I'm reading at the end of the 12 first paragraph under the "INTRODUCTION" section.</p> <p>13 MS. O'DELL: Of O'Brien?</p> <p>14 MR. HEGARTY: No. I'm sorry. No. Of Woolen 15 2022.</p> <p>16 MS. O'DELL: Thank you.</p> <p>17 THE WITNESS: I just want to clarify 18 something.</p> <p>19 We cite the explicit conclusion of O'Brien 20 that they didn't find a statistically significant 21 association. I would not interpret their results as 22 finding that. They did find a statistically significant 23 association, but they do conclude that they didn't. So 24 we cite what they concluded, but I don't agree that that 25 was what they found.</p>

1 BY MR. HEGARTY: 2 Q In your 2022 Woolen paper, you actually state 3 the main conclusion was that there was no statistically 4 significant association between genital talc use and 5 ovarian cancer, correct? 6 A I would state again: We cited what they 7 concluded, which is what they concluded. We cited 8 that -- their main conclusion. 9 Q Just agree -- can you agree, though, that in 10 the first paragraph under the "INTRODUCTION" section, 11 when you're referring to the Woolen paper, you use the 12 two words "main conclusion"? 13 A Again, in its main conclusion. So that's not 14 my main conclusion of their study. Those are important 15 differences. 16 Q Understood. 17 The 2022 [sic] O'Brien paper also found no 18 association between use of talc greater or equal to once 19 a week and ovarian cancer, correct? In other words, it 20 found no statistically significant association between 21 use at that amount -- that level and ovarian cancer, 22 right? 23 MS. O'DELL: Object to the form. 24 THE WITNESS: No, I -- I would not agree with 25 that conclusion.	Page 26 1 results where if it overlaps 1, you no longer believe 2 it's real is a little bit of an outdated interpretation. 3 So the movement is away from considering the edge of the 4 confidence interval, the edge of what we understand and, 5 rather, look at the confidence interval as giving you 6 some understanding of the precision of the estimate, but 7 the greatest strength is in the point estimate, and that 8 is for the 1.09. 9 And the fact that the confidence interval is 10 wider, I agree with you; in the past that would have -- 11 the language that would have been used is it's not 12 statistically significant, but -- but there's really 13 been a very strong shift away from that rigorous 14 interpretation of that, is if it's aligned towards the 15 most likely answer is, for that estimate, there's a 9 16 percent increase in risk and the precision is -- is 17 wider than -- than it -- than it would be if it didn't 18 overlap 1. 19 Q Having a confidence interval that crosses 1 20 also means you cannot reject a null hypothesis, correct? 21 A Again, I think historically that was often 22 used as a cut-off, a threshold, and I think -- I think 23 Dr. Rothman has written about this very eloquently, and 24 it's gotten hundreds of leading biostatisticians to sign 25 on to a statement that says: We no longer consider that
1 BY MR. HEGARTY: 2 Q What's wrong -- what part of my question do 3 you not agree with and tell me why? 4 A Several parts of it. 5 I think they had many results that show a 6 significant association between that powder use 1 -- 7 greater than once per week and ovarian cancer. So there 8 are -- I'm looking specifically at Table 3 in their 9 report. And in Table 3, they -- they look at the 10 results, use powder, at the top part of that greater 11 than one time per week. They show it for three 12 individual studies, and then the pooled estimate is 13 1.09. It goes from 0.97 to 1.23. I think that's an 14 important result. 15 And then in the bottom half of their table, 16 they show it for the pooled estimate greater than 1 who 17 used greater than once a week and have patent 18 reproductive tract. They show an estimate of 1.19, 1.03 19 to 1.37. I think both of those show a meaningful 20 association. 21 Q In epidemiologic terms, the fact that the 22 confidence interval range was from .97 to 1.23 with 23 regard to the 1.09 adjusted odds ratio means that you -- 24 means that the result could be due to chance, correct? 25 A I believe that interpretation of epidemiology	Page 27 Page 29 1 a meaningful conclusion. 2 Q Did you sign on to that statement? 3 A I'm not sure if I was at a medical school when 4 that statement was written, but -- 5 Q I'm talking about: Did you sign on to the 6 800-or-so -- 7 A I'm saying it was -- 8 Q -- group? 9 A -- it was before my time. It was before I did 10 training. They're even older than I am. 11 Q You mentioned a short time ago that you took 12 notes on the NCI PDQ? 13 A (Witness nods head.) 14 Q Is that correct? 15 A I did. 16 Q Did you review the NCI PDQ from March 6th, 17 2024? 18 A I did. 19 MR. HEGARTY: I'm going to mark that as my 20 next exhibit. 21 MS. O'DELL: I'm sorry. 22 THE WITNESS: I'm not sure about the date. It 23 was the recent PDQ. 24 MR. HEGARTY: Well, I'll go ahead and mark it, 25 and we'll all get to look at the date.

8 (Pages 26 - 29)

Golkow Technologies,

A Veritext Division

877-370-3377

www.veritext.com

<p style="text-align: right;">Page 30</p> <p>1 It should be the thick document. No, not that      2 one. It would be the --      3 MS. O'DELL: I would state --      4 MR. HEGARTY: -- that one.      5 MS. O'DELL: -- for the record: I haven't      6 seen the March 6th. The latest is the October 16th,      7 so --      8 MR. HEGARTY: So we'll mark -- I'm going to      9 mark it as Exhibit No. 5.      10 MS. O'DELL: So I'm sure Dr. Smith-Bindman was      11 probably looking at the October version.      12 MR. HEGARTY: I think we'll all see that it      13 has not changed with regard to the particular section      14 that we're interested in.      15 (Exhibit 5 was marked for identification by      16 the court reporter.)      17 MR. HEGARTY: So I've marked, as Exhibit No.      18 5, NCI PDQ for "Ovarian, Fallopian Tube, and Primary      19 Peritoneal Cancer Prevention, Health Professional      20 Version."      21 Q If you look over to the second-to-the-last      22 page of that document, do you see where it was updated      23 March 6th, 2024?      24 A I see the updated date, yep.      25 Q And that was just two weeks ago; is that</p>	<p style="text-align: right;">Page 32</p> <p>1 one prospective cohort study, correct?      2 A It does say that.      3 Q It is referring to your use of a subset of      4 data from the 2020 O'Brien study, correct?      5 MS. O'DELL: Object to form.      6 THE WITNESS: It's referring to my use of data      7 from the National -- the NHS Study I.      8 BY MR. HEGARTY:      9 Q That data was included in the 2020 O'Brien      10 study, correct?      11 A No. O'Brien looked at data from the NHS I.      12 O'Brien didn't look at data on frequent talc exposure      13 that -- as we defined it in that publication.      14 Q The NCI PDQ goes on to state that the subset      15 analysis of the prospective study was inconsistent with      16 the main findings of the original report, citing to the      17 2020 O'Brien study, correct?      18 A I'm not sure what that statement was supposed      19 to mean. I don't know if they're trying to say it was      20 inconsistent with the main findings of the initial      21 report of that population, the Gertig study, or if they      22 mean the findings that O'Brien found in -- in her      23 analysis of the NHS I, but in either case, the results      24 of that analysis were positive. So it's confusing to me      25 what they were intending to communicate with that</p>
<p style="text-align: right;">Page 31</p> <p>1 correct?      2 A Yes.      3 Q Would you please turn over to the section of      4 Exhibit No. 5 that talks about perineal talc exposure.      5 The copy I gave you is not page numbered.      6 A Yes. No, I'm there.      7 Q But it's towards the latter part of it. If      8 you could please tell me when you can find it.      9 A I'm there.      10 Q I'm really interested in asking you about the      11 portion of Exhibit No. 5, the NCI PDQ, that talks about      12 your study.      13 A Yes.      14 Q So if you could turn over to the next page      15 right in the middle section where it makes reference to      16 your study as -- as reference 10 and the O'Brien study      17 as reference 11.      18 Do you see where I am referring you to?      19 A I do.      20 Q The statements that are describing your paper      21 and your paper in reference to O'Brien are the same as      22 the previous PD- -- NCI PDQ you reviewed, correct?      23 A Correct.      24 Q The NCI PDQ refers to your study as a meta      25 analysis that used a highly selected subset analysis of</p>	<p style="text-align: right;">Page 33</p> <p>1 citation. In the -- in the O'Brien study, the results      2 are positive for the NHS I, and the original publication      3 in the Gertig study is positive -- the O'Brien study.      4 So I'm not sure which results they're      5 referring to, but in either case, whether it's the      6 original Gertig or the subset that O'Brien did, the      7 results in Woolen are consistent with both of those      8 prior publications.      9 Q Let's see if we can reach -- at least reach an      10 agreement as to the following: The NCI PDQ says: "The      11 subset analysis of the prospective study was      12 inconsistent with the main findings of the original      13 report."      14 It says that, correct?      15 A It does.      16 Q After that statement, it makes a reference to      17 11, which is the 2020 O'Brien study, correct?      18 A It does.      19 Q The next sentence after that citation to the      20 2020 O'Brien study says: "However, because of the      21 structure of this analysis, the results should be      22 interpreted with care."      23 Did I read that correctly --      24 A You --      25 Q -- and is that a correct statement from that</p>

<p>1 NCI PDQ?</p> <p>2 A You read it --</p> <p>3 MS. O'DELL: Object to form.</p> <p>4 THE WITNESS: You read it correctly. That</p> <p>5 does -- I don't know what that sentence is supposed to</p> <p>6 suggest.</p> <p>7 BY MR. HEGARTY:</p> <p>8 Q Do you agree with that sentence?</p> <p>9 A That the structure of the analysis -- the</p> <p>10 results should be interpreted -- I do not.</p> <p>11 The systematic review by Woolen was done at</p> <p>12 exemplary level and laid out every step of the way and</p> <p>13 followed every guideline. So I'm not sure what they</p> <p>14 mean by that.</p> <p>15 THE REPORTER: Counsel, I believe someone is</p> <p>16 trying to join by Zoom.</p> <p>17 MR. HEGARTY: Okay. Let's go off the record.</p> <p>18 (Mr. Lapinski joined the deposition</p> <p>19 proceedings.)</p> <p>20 BY MR. HEGARTY:</p> <p>21 Q The statements that we just went over in the</p> <p>22 March 2024 NCI PDQ have been in that NCI PDQ in the</p> <p>23 prior versions for at least a year.</p> <p>24 Can we agree with that?</p> <p>25 MS. O'DELL: Object to the form.</p>	<p>Page 34</p> <p>1 really shoddy piece of work.</p> <p>2 And the way that process works is it's not a</p> <p>3 process that's peer-reviewed. It's not open for</p> <p>4 external criticism. There's no formal mechanism to say</p> <p>5 that that work is shoddy work, and it doesn't really</p> <p>6 have -- other than the context of this case, does not</p> <p>7 have much of an impact on people's thinking. So there's</p> <p>8 just no mechanism to say this is a terrible report.</p> <p>9 Q Do you know any of the individuals on the</p> <p>10 current NCI PDQ board?</p> <p>11 A I'm not --</p> <p>12 Q I can bring it up if we need to.</p> <p>13 A I think we'd have to. I'm not sure. The</p> <p>14 person who ran it when I was on it is long gone.</p> <p>15 Q You do agree, though, that because of your</p> <p>16 involvement, you can contact NCI PDQ board members and</p> <p>17 comment on what is in an NCI PDQ, correct?</p> <p>18 A There is nothing that would hinder me from</p> <p>19 contacting them, but there's no process for that to be</p> <p>20 formally included in their process of -- of rereviewing.</p> <p>21 Q Do you have any intention, sitting here today,</p> <p>22 to reach out to any of the current board members about</p> <p>23 the statements in the NCI PDQ as it relates to your</p> <p>24 paper?</p> <p>25 A I do not.</p>	<p>Page 35</p> <p>1 Q Yet you have, for various -- over various</p> <p>2 times in your career, with regard to various parts of</p> <p>3 your work, given interviews that have been cited in</p> <p>4 newspaper articles, correct?</p> <p>5 A Across all topics?</p> <p>6 Q Across whatever kind of topics you're -- that</p> <p>7 are -- let me start over again.</p> <p>8 With regard to all topics.</p> <p>9 A Yes, I have.</p> <p>10 Q Across all topics.</p> <p>11 A Yes, I have.</p> <p>12 Q You've also done videos on YouTube, correct?</p> <p>13 A I believe that educational meetings that I've</p> <p>14 led have been posted on YouTube, but I -- I've</p> <p>15 personally never been involved in that. So I led a</p> <p>16 meeting in the fall with a hundred lecturers, and I --</p> <p>17 someone on my team uploaded them, but I've never done</p> <p>18 informational interviews for YouTube.</p> <p>19 Q Do you have social media accounts?</p> <p>20 A I -- I believe that my lab has a Twitter</p> <p>21 account. I don't think we post very much, and I</p> <p>22 personally never post on it. I can't actually tell you</p> <p>23 what we posted.</p> <p>24 Q Did you help create any of the content on your</p> <p>25 university's website as it relates to you?</p>
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

<p>1 A Yes.</p> <p>2 Q You have commented on the potential effects of 3 radiation and cancer in various newspaper articles, 4 correct?</p> <p>5 A Yes.</p> <p>6 Q Have you ever contacted a newspaper article, 7 ever done a video on YouTube, ever put anything on the 8 content of your university website as it relates to the 9 NCI PDQ's characterization of your Woolen paper?</p> <p>10 A No.</p> <p>11 Q Have you used any of these communication 12 outlets in any way to discuss your Woolen paper in any 13 respect?</p> <p>14 A I don't believe so.</p> <p>15 Q Have you used any of these communication 16 outlets to discuss your opinions in the talc litigation?</p> <p>17 A I have not.</p> <p>18 Can -- can -- I don't know if I can clarify 19 something that I said. I have spoken to newspapers and 20 various outlets about research projects that I've been 21 contacted about. I have never reached out to newspapers 22 or any other outlet to describe my work in the absence 23 of it being generated from them to ask about my -- about 24 my work.</p> <p>25 Q Now, with regard to your 2022 article, that</p>	<p>Page 38</p> <p>1 BY MR. HEGARTY:</p> <p>2 Q Are you talking about an editor at the journal 3 level?</p> <p>4 A No. There's a editor that I've worked with on 5 various papers who doesn't bring content expertise, but 6 who has edited some of our papers before publication.</p> <p>7 Q Who is that?</p> <p>8 A Chris Tachibana. I don't -- I actually have 9 no recollection if she was involved or not, but I was 10 looking if we had thanked her. I don't remember, but 11 that's a possibility.</p> <p>12 Q At the time the Woolen paper was published in 13 2022, did either Dr. Woolen or Dr. Lazar work for you?</p> <p>14 A No. No. No.</p> <p>15 Q At the time of publication, were you 16 supervising them in any way?</p> <p>17 A No.</p> <p>18 Q Were you filling out evaluations for them?</p> <p>19 A No.</p> <p>20 Q What funds paid for their time?</p> <p>21 A I have academic funds that I can use for that 22 kind of work. Dr. Woolen was not paid, and Dr. Lazar 23 was paid as a biostatistical consultant from one of the 24 funds.</p> <p>25 Q Is there any documentation of the amount of</p>
<p>1 is, the Woolen article, you collaborated with Sean 2 Woolen and Ann Lazar, correct?</p> <p>3 A Yes.</p> <p>4 Q At the time that you began collaborating with 5 them about the 2022 Woolen paper -- that became the 2022 6 Woolen paper, were they aware that you are an expert 7 witness for Plaintiffs in talc cases?</p> <p>8 A Absolutely.</p> <p>9 Q Other than you and Dr. Woolen and Dr. Lazar, 10 was anyone else involved in any aspect of the study, its 11 preparation and publication?</p> <p>12 MS. O'DELL: Let's make -- Mark, during 13 Dr. Smith-Bindman's October 1nd, 2020, deposition -- if 14 you're laying the foundation -- I'm not objecting. I'm 15 just saying: There was a long line of questions that 16 followed all of this.</p> <p>17 MR. HEGARTY: Understood, and I'm -- just one 18 question about --</p> <p>19 MS. O'DELL: Sure.</p> <p>20 MR. HEGARTY: -- about that.</p> <p>21 MS. O'DELL: I just wanted to make you aware 22 of that.</p> <p>23 THE WITNESS: I'm hesitating because I do not 24 remember if we had an editor who edited the manuscript 25 or not.</p>	<p>Page 39</p> <p>1 cost that went into getting the Woolen paper published?</p> <p>2 MS. O'DELL: Object to the form.</p> <p>3 THE WITNESS: There would be a track record of 4 having paid it. It almost certainly wouldn't have gone 5 to Dr. Lazar. It would have gone to the statistical 6 bio-consulting service, and so it would be possible to 7 possibly find records of how that were paid.</p> <p>8 BY MR. HEGARTY:</p> <p>9 Q Are those documents you provided to counsel 10 for Plaintiffs?</p> <p>11 MS. O'DELL: I'll represent: No.</p> <p>12 BY MR. HEGARTY:</p> <p>13 Q Are there any other accounting documents that 14 you're aware of that would relate to the work in getting 15 -- in getting the Woolen paper published; that is, the 16 -- where you had to itemize the -- the cost and expenses 17 that went into the published paper?</p> <p>18 MS. O'DELL: Object to the form.</p> <p>19 THE WITNESS: The only cost that could exist 20 would be the cost to pay the biostatistical consultants, 21 and that would be findable with some digging through the 22 financial records. Not by me, but someone at UCSF, and 23 I don't believe that this journal has a publication 24 cost, but if there -- if there was, there could be a 25 cost for that.</p>

1 BY MR. HEGARTY: 2 Q You said that you have access to funding -- 3 funding as part of your work. 4 Do you have to do an accounting, that is, 5 prepare a physical document of the accounting of use of 6 that funds -- did you have to prepare an accounting, as 7 far as use of that funds, for the Woolen paper? 8 A The amount of money was -- was not very much, 9 and if you're spending money on the -- the -- it's 10 called the CTSI, the biostatistical consulting, there 11 would be no other documentation needed. 12 In general, I have incredible detailed records 13 I have to provide for everything I spend, but internal 14 UCSF money for biostatistical consulting would be just 15 accepted as necessary. 16 Q So would that have been the only expense that 17 you would have had as part of the 2022 Woolen paper? 18 A Yes. 19 Q And as you indicated, there would be no 20 separate document accounting for what that expense would 21 be; is that right? 22 A That's correct. 23 Q The 2022 Woolen paper focused on frequency of 24 talcum powder use, correct? 25 A Yes.	Page 42  1 personally answer the question have I ever used it. I 2 think that -- kind of, I've been around talcum powder, 3 but I don't know if I ever used it; whereas, if you're 4 asking women are they using it frequently, meaning kind 5 of every day, I think women would remember that very 6 clearly. 7 Q Let me ask it, then, still a different way. 8 If we're talking about not just did you use it 9 frequently, but if you're talking about the specific 10 number of times you used it in a month versus just if 11 you ever used it, do you agree that there's more 12 likelihood for misremembering the number of times you 13 use it in a month versus ever or never using it? 14 A I -- I'm not sure that I agree with that. I 15 just -- I couldn't answer the question of ever/not ever. 16 I'd be unable to. Whereas, if your question is getting 17 at would a woman know if she used it three or four times 18 a week, is there lack of precision between three and 19 four, which I think is what you're getting at, there 20 might be. But if there's lack of precision between 21 using it a lot versus have you ever used it, I'm not 22 sure that "Have you ever used it?" is a reliable answer 23 just because I couldn't answer that question. 24 MR. HEGARTY: Let's go off the record. 25 (Recess.)
Page 43  1 Q You agree that there is more likelihood for 2 exposure misclassification when patients provide 3 frequency data versus "ever/never" use data, correct? 4 A I would not agree with that. 5 Q Why would you not agree with that? 6 A I think "ever" is a very broad category. As I 7 state in the report, that could be once or twice. It 8 could be a thousand or 10,000 times. It's such a broad 9 range that I think perhaps the capacity to say ever 10 "yes" or "no" might be easy to remember, but it wouldn't 11 be a meaningful remember; whereas, I think asking about 12 frequent talcum powder use is asking about a habitual 13 activity that I think women are likely to remember. 14 And I think in detailed surveys the most 15 common amount of talcum powder use is daily, and I think 16 women who use it daily would have a good remembrance 17 that this was part of their daily routine, like 18 moisturizer or something like that. 19 Q Let me ask it in a different way, which I 20 think tracks what you're saying. 21 Do you agree that there is more likelihood for 22 misremembering the frequency of talcum powder use as 23 compared to whether you ever use talcum powder? 24 A I -- I do understand the question, and I'm not 25 sure that I would agree with that. I think I couldn't	Page 45  1 MR. HEGARTY: We're back on the record after a 2 short break. I want to leave the PDQ question, Doctor, 3 that we just talked about, but I did have the 4 opportunity to pull up the PDQ screen and prevention 5 editorial board from the website. 6 Q Would you mind scrolling through that website 7 on my laptop and tell me if you know any of the 8 individuals that are listed there. 9 A I know Joanne Elmore from UCLA, and I think I 10 might know Joe Wrubbel from Connecticut, but I can't 11 remember. 12 Q How well -- 13 A Not well. 14 Q How well do you know Dr. Elmore? 15 A Fairly well. 16 Q How would you describe her reputation-wise? 17 A It's good. 18 Q Do you have any criticisms of her capabilities 19 as a scientist? 20 A I don't. 21 Q Any criticisms you just provided at this 22 deposition as it relates to their review of perineal 23 talc as set out in the NCI PDQ you're saying apply to 24 her too, right? 25 A The way the reviews get done is an individual

<p style="text-align: right;">Page 46</p> <p>1 person takes the lead on each one.</p> <p>2 I am very confident that Joanne Elmore didn't</p> <p>3 do that particular review.</p> <p>4 Q Every board member of the NCI PDQ signs off on</p> <p>5 every sentence in the NCI PDQ?</p> <p>6 A No, I don't think that's true.</p> <p>7 Q And I don't mean that in a formal way, but</p> <p>8 they put their name to the -- the NCI PDQ as being on</p> <p>9 the board, correct?</p> <p>10 MS. O'DELL: Object to the form.</p> <p>11 THE WITNESS: No, I don't -- I don't think</p> <p>12 it's that kind of document. I think there are documents</p> <p>13 that the NCI puts out that have that kind of weight.</p> <p>14 This does not.</p> <p>15 This is a group of scientists who, together,</p> <p>16 help the public and other physicians understand the</p> <p>17 medical literature, but it's not a degree of every one</p> <p>18 of those scientists stands behind everything that comes</p> <p>19 out of that. There remains a lot of internal</p> <p>20 disagreements about things that get published on the</p> <p>21 PDQ. It's not a uniform, "We support this."</p> <p>22 BY MR. HEGARTY:</p> <p>23 Q You have no personal knowledge of Dr. Elmore's</p> <p>24 or anyone else on the board's involvement with the NCI</p> <p>25 PDQ that we marked as Exhibit No. 5 in this case,</p>	<p style="text-align: right;">Page 48</p> <p>1 MS. O'DELL: Object to the form. Assumes</p> <p>2 facts.</p> <p>3 THE WITNESS: I disagree with almost every</p> <p>4 statement in that PDQ. If it were Joanne's or if Joanne</p> <p>5 agreed to it, I'd be happy to have a vigorous discussion</p> <p>6 with Joanne, and if we end up being together in some</p> <p>7 location in the near future, I will, for your</p> <p>8 suggestion, raise it with her and share my views of it.</p> <p>9 BY MR. HEGARTY:</p> <p>10 Q But what you know about Dr. Elmore, is she</p> <p>11 capable of reviewing the studies that you reviewed,</p> <p>12 including those in the NCI PDQ, and coming to</p> <p>13 conclusions about what they mean?</p> <p>14 A I -- I respect Joanne as an epidemiologist. I</p> <p>15 think she would be able to do such a task.</p> <p>16 Q I want to talk about specific parts of your --</p> <p>17 of the 2022 Woolen paper, and I'm going to cite to</p> <p>18 specific parts of it.</p> <p>19 So do you have a copy in front of you?</p> <p>20 A I do.</p> <p>21 Q First of all, the study does not report on the</p> <p>22 finding -- does not report findings on any specific sub</p> <p>23 type of ovarian cancer, correct?</p> <p>24 A That's correct.</p> <p>25 Q If you look at the background section, the</p>
<p style="text-align: right;">Page 47</p> <p>1 correct?</p> <p>2 A I do not.</p> <p>3 Q You have no personal knowledge of what any of</p> <p>4 the board members did with regard to reviewing of the</p> <p>5 documents or preparing the NCI PDQ we've marked as</p> <p>6 Exhibit No. 5 --</p> <p>7 A I --</p> <p>8 Q -- correct?</p> <p>9 A -- do not.</p> <p>10 Q Do you feel comfortable enough with Dr. Elmore</p> <p>11 to talk with her about the NCI PDQ?</p> <p>12 A I would, yeah.</p> <p>13 Q If -- assume for my question -- the purpose of</p> <p>14 my question, hypothetical, that Dr. Elmore agrees with</p> <p>15 what's set out in the NCI PDQ with regard to perineal</p> <p>16 talc exposure.</p> <p>17 Would the criticisms that you have told me</p> <p>18 today about it apply to her as well?</p> <p>19 MS. O'DELL: Object to the form.</p> <p>20 THE WITNESS: I don't believe I criticized a</p> <p>21 person. I criticized the quality of the work, and</p> <p>22 whoever wrote that did a very poor job.</p> <p>23 BY MR. HEGARTY:</p> <p>24 Q And if Dr. Elmore reviewed it and found it to</p> <p>25 be correct, would you be critical of her?</p>	<p style="text-align: right;">Page 49</p> <p>1 very first section on the first page, the first sentence</p> <p>2 says (as read): "Risk of ovarian cancer in women with</p> <p>3 frequent perineal talcum powder product is not well</p> <p>4 understood."</p> <p>5 Did I read that correctly?</p> <p>6 MS. O'DELL: Can I just ask -- I'm sorry,</p> <p>7 Mark. I got lost. You're in Woolen --</p> <p>8 MR. HEGARTY: I'm in the very first page, the</p> <p>9 very first sentence.</p> <p>10 MS. O'DELL: Oh, yeah. I'm sorry.</p> <p>11 THE WITNESS: Yeah.</p> <p>12 MS. O'DELL: Okay. Forgive. Thank you.</p> <p>13 THE WITNESS: Yes. And I'm sorry. You're</p> <p>14 asking me if that is what the first sentence says?</p> <p>15 MR. HEGARTY: Yes.</p> <p>16 THE WITNESS: Yes.</p> <p>17 BY MR. HEGARTY:</p> <p>18 Q That was -- that statement was true in 2022,</p> <p>19 and it's true today, correct?</p> <p>20 A I believe our systematic review changed that</p> <p>21 sentence. I think it's much better understood since</p> <p>22 this publication came out.</p> <p>23 Q In 2022 when you wrote that sentence, that</p> <p>24 sentence was true, correct?</p> <p>25 A Yes.</p>

13 (Pages 46 - 49)

<p style="text-align: right;">Page 50</p> <p>1 Q Now, this study looked at frequency only, that      2 is, frequency of talcum powder use only, correct?      3 A Yes.      4 Q It did not account for duration of use,      5 correct?      6 A Correct.      7 Q It does not measure cumulative use, correct?      8 A Correct.      9 Q So --      10 A I'm hesitating. The focus was on frequency of      11 use. For many of the included articles, they provided      12 information on cumulative use.      13 Q My question, though, was: Your 2022 Woolen      14 paper does not measure cumulative use, correct?      15 MS. O'DELL: Object to form.      16 MR. HEGARTY: Or let me say it differently.      17 THE WITNESS: Yeah.      18 BY MR. HEGARTY:      19 Q Your 2020 [sic] Woolen paper does not report      20 findings as to cumulative use?      21 A Correct.      22 Q So frequency of use is an acceptable measure      23 of exposure in an epidemiologic study involving talc,      24 correct?      25 A Yes.</p>	<p style="text-align: right;">Page 52</p> <p>1 me restate that.      2 You did not state in that conclusion that      3 frequent perineal powder exposure causes ovarian cancer,      4 correct?      5 A Correct.      6 Q In fact, nowhere in this paper do you say that      7 talcum powder use causes ovarian cancer, correct?      8 A I would have to read it more carefully, but I      9 -- I wouldn't be surprised if what you're saying is      10 true. I would have to read it to -- to remember that.      11 Q Looking over at the "INTRODUCTION" section,      12 right-hand column, second paragraph, the first line says      13 (as read): "The differences in conclusions between the      14 meta analyses are at least partially due to the      15 inconsistent talcum powder exposure questions regarding      16 the frequency and type of exposure."      17 Did I read that correctly?      18 A Yes.      19 Q Can you cite for me any publication in any      20 journal who has made a similar statement as the one I      21 just read?      22 MS. O'DELL: Object to the form. Vague.      23 THE WITNESS: My recollection is that maybe in      24 the Health Canada and Taher studies they might have said      25 something about -- about this similar issue.</p>
<p style="text-align: right;">Page 51</p> <p>1 Q Looking at the "METHODS" section, it says that      2 the quality assessment using a Newcastle-Ottawa Scale      3 was performed independently by two reviewers.      4 Who were those two reviewers?      5 A Sean Woolen and myself.      6 Q Had you ever used a Newcastle-Ottawa Scale      7 prior to this publication?      8 A I had not.      9 Q I'm sorry?      10 A I had not.      11 Q Okay. Thank you.      12 Looking at the "CONCLUSIONS" section at the      13 bottom of the first page, left-hand column, it states:      14 "This review suggests an increased risk of ovarian      15 cancer associated with frequent perineal powder exposure      16 of 31 to 65%," correct?      17 MS. O'DELL: You're back in the abstract?      18 MR. HEGARTY: I'm still in the abstract.      19 That's what I said. First page --      20 THE WITNESS: Still in the abstract.      21 MR. HEGARTY: -- bottom left-hand corner,      22 conclusion.      23 Q Did I read that conclusion correctly?      24 A Yes.      25 Q You did not include or -- let me state -- let</p>	<p style="text-align: right;">Page 53</p> <p>1 BY MR. HEGARTY:      2 Q Please turn to the next page.      3 Under the section "Search Strategy and      4 Information Sources" --      5 A Mm-hmm.      6 Q -- do you see that section?      7 A Mm-hmm.      8 Q It says, in the first line (as read):      9 "Comprehensive searches were performed by an expert      10 health science informationist -- informationist from      11 inception of the relevant databases" in August -- "to      12 August 2nd, 2022 [sic]."      13 Who was that?      14 A At one of the UCSF sites at Mt. Zion they have      15 a amazing library search team of professionals. So it      16 would have been someone in that group.      17 Q Do you know who that someone was --      18 A No.      19 Q -- by name?      20 A No.      21 Q Looking under the "Eligibility Criteria and      22 Study Selection" section, second paragraph, the first      23 couple lines reads (as read): "Studies were screened      24 for inclusion using prespecified selection criteria by a      25 single author S.W. Selection criteria included</p>

14 (Pages 50 - 53)

<p style="text-align: right;">Page 54</p> <p>1 publication of primary data, reporting on multiple times      2 per week (greater than or equal to two times per week)      3 perineal exposure to talcum powder including direct      4 application of talcum powder to the perineum and rectum,      5 application to underwear or sanitary napkins, or on      6 birth control devices -- devices like diaphragms and      7 risk for ovarian malignancy."</p> <p>8 Did I read that correctly?</p> <p>9 A Yes.</p> <p>10 Q That described the selection criteria for the      11 studies to include, correct?</p> <p>12 A Yes.</p> <p>13 Q Now, the O'Brien data did not meet that      14 criteria, correct?</p> <p>15 A Correct.</p> <p>16 Q Why did you include it, then?</p> <p>17 A We didn't include the O'Brien study. We      18 included data from the Nurses' Health Initiative Study,      19 and I learned about that study in -- in more detail from      20 the O'Brien publication, but we didn't use the O'Brien      21 publication. It didn't -- none of the -- none of the      22 pieces that they pulled from the existing cohorts could      23 be used. So that was a second request to get      24 unpublished data from whichever the cohorts had relevant      25 data. So that's described in the next paragraph.</p>	<p style="text-align: right;">Page 56</p> <p>1 Study because there were two patients who reported the      2 high-use category, and that just wasn't enough to be      3 meaningful. So they told us there were only two      4 patients who reported frequent use in that study.</p> <p>5 Q That was provided to you orally?</p> <p>6 A I think it was probably a written document      7 from O'Brien to Woolen explaining that.</p> <p>8 Q So does that mean that you never got access to      9 the Sister Study data?</p> <p>10 A That's correct.</p> <p>11 Q So the statement at the end of this is based      12 on the statement that the number that met your criteria      13 was only two?</p> <p>14 A Yes.</p> <p>15 Q Turning to the section "Data Extraction," in      16 the middle it says that the reference group was "women      17 who reported no talc exposure"; is that accurate? In      18 other words, you compared the group with frequent use      19 versus women who had no talc exposure?</p> <p>20 A Yes.</p> <p>21 Q The next line says: "When duplicate reports      22 of the same subject were published, the publication      23 reporting the highest talc use was selected."</p> <p>24 Was there any duplication of study subjects      25 included in any of the results?</p>
<p style="text-align: right;">Page 55</p> <p>1 Q The inclusion criteria set out in the section      2 "Eligibility Criteria and Study Selection" did not      3 include a requirement that the women in the study had      4 patent tubes, correct?</p> <p>5 A Correct.</p> <p>6 Q Carrying over still in the same eligibility      7 criteria section to the next paragraph at the top on the      8 right-hand column, there's a reference to the Sister      9 Study at the very end of that section, correct?</p> <p>10 A Yes.</p> <p>11 Q The Sister Study actually collected data on      12 two or more times of talc use per week, correct?</p> <p>13 A We looked at the study protocols for all of      14 those, and indeed the Sister Study did have questions      15 about the number of times per week in their -- in their      16 questionnaire.</p> <p>17 Q Are you saying, in this part of the paper,      18 that there were only two women who met the eligibility      19 requirement from the Sister Study data?</p> <p>20 A Yes. We reached out to the person who      21 basically oversees the data for the Sister Study and the      22 NH I [sic] study. Because they had the relevant      23 questions in the Sister Study and in the NH -- NHS I      24 study, we asked for those data, and what we were told is      25 that -- they wouldn't share the data for the Sister</p>	<p style="text-align: right;">Page 57</p> <p>1 A Not that I remember. I think we were careful      2 to try to make sure that patients were only reported      3 once.</p> <p>4 Q The very end of that section says:      5 "Disagreements in data extraction were resolved by      6 consensus."</p> <p>7 Who were they resolved between by consensus?      8 In other words, who was making that resolution?</p> <p>9 A The three authors.</p> <p>10 I want to correct something from -- the paper      11 says the data extraction were performed by two authors,      12 which it were -- which it was, but Dr. Lazar actually      13 did the data extraction for all those studies as well.</p> <p>14 Q Please turn over to the page that has Table 1      15 on it and Table 2.</p> <p>16 A Yes.</p> <p>17 Q Looking at the text, you know, on the      18 left-hand column, it refers to the age range of included      19 women as being between 18 and 79.</p> <p>20 Is that at the point in time -- at what point      21 in time is that? At the time of their reporting of talc      22 use or at what other -- at what time?</p> <p>23 A For the case control studies, they would      24 report when they were enrolled in the trial. For the      25 NHS I, I -- I don't remember if it was when they were</p>

15 (Pages 54 - 57)

<p style="text-align: right;">Page 58</p> <p>1 enrolled in the trial or at the end of follow-up. I      2 believe it's at enrollment, but I'd have to check.      3 Q Carrying over to the next column, it states      4 that the range of frequent talcum powder use was defined      5 as four to seven times per week, correct?      6 A Can you say that one more time?      7 Q Sure.      8 Carrying over to the -- to the right-hand      9 column at the text on the page we're looking at, it says      10 the range of frequent talcum powder use was defined as      11 four to seven times per week, correct?      12 A Yes.      13 Q Do you recall, in your prior reports in the      14 MDL, you defined the frequency range as three or more      15 times per week?      16 A Yes.      17 Q And with regard to what you actually report in      18 the findings, you report yet a different number,      19 correct?      20 MS. O'DELL: Object to the form.      21 THE WITNESS: I think there's a difference      22 between what we set out to require for inclusion and      23 what the articles actually found. So we set out to      24 include use that was at least several times per week,      25 but the articles that reported on frequent use, in fact,</p>	<p style="text-align: right;">Page 60</p> <p>1 exposure.      2 BY MR. HEGARTY:      3 Q In your simple math, did you assume one time      4 per day of use?      5 A When it said 20 times per month, we took that      6 to mean 20 days of exposure.      7 Q What did you do when it said 10,000 or more      8 lifetime uses?      9 A We divided it by, I believe, the age of the      10 average person to come up with an estimate of how many      11 times per week they would have used talc to get      12 approximately that -- that level, but we included      13 studies if the amount of exposure would have been at      14 least two times per -- per week, but assuming one time      15 per day.      16 Q That assumption would not account for women if      17 they reported using -- if they reported, as far as their      18 lifetime use, based on five times use a day, correct?      19 A That's correct.      20 Q The Cook 2000 -- or -- I'm sorry -- the Cook      21 1997 paper also reported use of between 5- and 10,000      22 lifetime uses, correct?      23 A Do you have the Cook paper?      24 Q I do not have the Cook paper.      25 Let's go off the record real quick.</p>
<p style="text-align: right;">Page 59</p> <p>1 had average use that was higher than we required.      2 BY MR. HEGARTY:      3 Q In the end, you reported on as frequent use      4 two or more times per week, correct?      5 A Yeah.      6 Q But the initial eligibility requirement was      7 four to seven times per week, correct?      8 MS. O'DELL: Object to the form.      9 THE WITNESS: No, it didn't say that. The      10 eligibility was greater than two times per week, but the      11 articles ended up identifying higher use than that.      12 BY MR. HEGARTY:      13 Q Looking down at Table No. 2, only four studies      14 report actual weekly talcum powder use: Booth, Mills,      15 Schildkraut, and O'Brien, correct?      16 MS. O'DELL: Object to the --      17 THE WITNESS: I would agree if you look in      18 this table. Some of the numbers show times per week,      19 and some show a lifetime exposure.      20 For each of those papers that had a lifetime      21 exposure, we calculated how many years the women were      22 followed, how many times per week that 10,000 lifetime      23 exposure would correspond to. So we reported in the      24 language that they use, but when you do the simple math,      25 you end up getting a way to estimate the weekly</p>	<p style="text-align: right;">Page 61</p> <p>1 (Discussion Off the Record.)      2 MR. HEGARTY: Okay. We can go back on the      3 record.      4 Q When we took a short break, Doctor, I was      5 asking you about the Cook 1997 paper, and we both had an      6 opportunity to pull that up.      7 And are you looking at it now?      8 A I am.      9 Q And in particular, Table 3 provides use of      10 talcum powder between 5,001 and 10,000 uses for lifetime      11 days, correct?      12 A Yes.      13 Q And from that -- go ahead.      14 A I'm sorry. It says "lifetime days."      15 When you asked your question earlier about if      16 a person had used it five times a day, in this case, it      17 would count once for each day the way they extracted. I      18 never thought about that -- or hadn't thought about the      19 issue in ages, but --      20 Q Okay. Thank --      21 A -- so this would take that away.      22 Q But with regard to Table 3, you used the      23 number of greater than 10,000, correct?      24 A Yes.      25 Q Cook also provides from 5,001 to 10,000 uses,</p>

16 (Pages 58 - 61)

<p>1 correct?</p> <p>2 A Yes.</p> <p>3 Q You did not use that data, correct?</p> <p>4 A Did not.</p> <p>5 Q Why did you not use that data?</p> <p>6 A As we laid out in the "METHODS," we took the 7 highest frequency use, and so 10,000 is the highest 8 frequency use.</p> <p>9 Q So even though you might have had data that 10 was greater than two times per week, you still took the 11 highest data that was available, correct?</p> <p>12 A Yes.</p> <p>13 Q Why did you do that? Let me ask it a 14 different way.</p> <p>15 If you had additional data that would then 16 have satisfied what you were reporting on in this paper, 17 why did you not include it too?</p> <p>18 A There are several reasons. First, we were 19 trying to get at -- I think we say in the paper 20 approximate daily use. So that would be the highest 21 number. So if someone -- if there was a material 22 difference between women who reported twice a week, four 23 times a week or seven times a week, we were trying to 24 get at seven times a week, the highest use. So that's 25 the first.</p>	<p>Page 62</p> <p>1 quick.</p> <p>2 (Discussion Off the Record.)</p> <p>3 MR. HEGARTY: We can go back on the record.</p> <p>4 We took just a moment to find the Harlow 1992 paper.</p> <p>5 Q I was looking at the relative risk number that 6 you use for Harlow, which was the 1.8 number with a 7 confidence interval of 1.1 to 3.0 that is shown in Table 8 1 for greater than 10,000.</p> <p>9 Do you see where I'm referring to?</p> <p>10 A I'm seeing for greater than 30 applications 11 per month in Table 2.</p> <p>12 Am I in the wrong table?</p> <p>13 Q Okay. Let me come back out to Table 2.</p> <p>14 A I'm sorry.</p> <p>15 Q Which number did you use?</p> <p>16 A It seems to be the same number, but let me 17 see. Applications per month.</p> <p>18 Q And as you're saying that -- because you 19 reported on greater than 10,000 uses, which would more 20 correspond -- which would correspond to what's reported 21 in Table 3, correct?</p> <p>22 A The point estimate is the same. So I just 23 need to look at my paper to see what number corresponds 24 to the number.</p> <p>25 I think I -- I think I gave you that number</p>
<p>1 The second is you can't pull multiple data 2 points from one study in a systematic review method.</p> <p>3 You have to represent each study with a single estimate.</p> <p>4 There are ways of combining data within one systematic 5 review and then using that in a weighted way in an 6 overall review, and I've done that for a systematic 7 review on an unrelated topic, but in general, each study 8 should be represented by a single reflection of the 9 work. So you can't take multiple points. It just would 10 -- it would make it impossible to weight the work 11 appropriately.</p> <p>12 Q You did that not only as to the Cook paper, 13 but there were other papers as well that reported on 14 frequent use that might have been in the greater than 2 15 times a week, but if it had a greater number, you used 16 the greater number?</p> <p>17 A That's correct.</p> <p>18 Q There was one set of numbers that I could not 19 quantify as it relates to the number of exposed cases 20 and the number of exposed controls, and that is the 21 Harlow 1992 paper.</p> <p>22 Do you have the Harlow 1992 paper?</p> <p>23 A I think you -- I think you nailed the two 24 papers that I have to find on my computer.</p> <p>25 MR. HEGARTY: Let's go off the record real</p>	<p>Page 63</p> <p>1 incorrectly. I think you are correct that for Harlow 2 58 ...</p> <p>3 (Pause.)</p> <p>4 Q And what I'm asking about is --</p> <p>5 A Yeah.</p> <p>6 Q -- for the number greater than 10,000, I'm not 7 seeing the numbers 58 and 41 that you report in Table 3, 8 and I'm hoping you can explain the difference.</p> <p>9 Let's go ahead and go off the record.</p> <p>10 (Discussion Off the Record.)</p> <p>11 MR. HEGARTY: Okay. Let's go back on the 12 record.</p> <p>13 When we took a short break, I asked 14 Dr. Smith-Bindman to explain to me, from using Table 3, 15 the -- the numbers reported there as far as the cases it 16 controls versus the numbers reported in the Woolen 2022 17 paper in Table No. 2.</p> <p>18 Q Are you -- are you ready to do that?</p> <p>19 A I am.</p> <p>20 Q Okay. Can you explain it to me?</p> <p>21 A I can.</p> <p>22 So the numbers that we extracted from the 23 Harlow paper were not from Table 3, but they're from 24 Table 2 that talk about the applications of talc per 25 month. So the number that was actually extracted was</p>

<p style="text-align: right;">Page 66</p> <p>1 greater than 30 applications per month from Table 2.      2 That shows you the 58 cases and 41 controls that align      3 with the numbers in both Table 2 and Figure 2.      4 Q Why did you use those numbers from the greater      5 than 30 times per month from Table 2 versus the numbers      6 from the greater than 10,000 times, which you reported      7 in your paper, that are in Table 3?      8 MS. O'DELL: Object to the form.      9 Table 3 in Harlow?      10 MR. HEGARTY: In Harlow. Yes. Thank you.      11 THE WITNESS: In Harlow.      12 I think we were trying to get at the most      13 number of applications per month, and the greater than      14 30 most directly reflects that question, how many times      15 per month, and that's -- the answer is 30. That's      16 daily.      17 BY MR. HEGARTY:      18 Q A related question is, then: Why didn't you      19 report in this -- in Table 2 of your Woolen paper the      20 greater-than-30-times-per-month number?      21 A I believe that's an error.      22 Q Okay. Thank you.      23 If you look at the bottom of this -- of the      24 page we're looking at, the footnotes under Table 2,      25 there's a reference in the last footnote to only using</p>	<p style="text-align: right;">Page 68</p> <p>1 A Yes.      2 Q What other publications specifically called      3 out their data as "women with intact fallopian tubes"?      4 A I think the other studies looked at open tubes      5 versus closed tubes and showed the results for ovarian      6 cancer risk as it varied by talc and whether the tubes      7 were open or not. Of those studies that showed that      8 patent fallopian tubes had higher risks were Kramer,      9 Harlow, and Whittlemore. I think in terms of reporting      10 it that way, I think -- I believe that Whittlemore      11 reported it that way; although, it was a little bit      12 ambiguous in that publication.      13 Q Do you agree that there were at least some of      14 the -- at least some of the studies in Table 2 did not      15 break down their figures by whether the women had intact      16 tubes or non-intact tubes?      17 A Absolutely.      18 Q So the extent that you then used O'Brien data      19 on women with intact tubes, that's potentially      20 inconsistent with some of the other studies who did not      21 report one way or the other, correct?      22 MS. O'DELL: Object to the form.      23 I think Dr. Smith-Bindman said repeatedly it's      24 not the O'Brien data; it's the Nurses' Health Study      25 data.</p>
<p style="text-align: right;">Page 67</p> <p>1 the -- the data from -- that O'Brien -- that Dr. O'Brien      2 provided --      3 A I'm sorry.      4 Q I'm sorry.      5 A We've left --      6 Q The very -- the very last footnote --      7 A No. We're back on Woolen. We've left Harlow.      8 Q No, no -- yeah, we left Harlow. We're now      9 back to your Woolen paper.      10 A Okay. Fantastic. Let me move. Let me move.      11 Q Okay. I'm glad -- now we're on Table 2 on      12 your Woolen paper in -- at the bottom of that page in      13 Footnote 5.      14 First of all, we talked earlier about you      15 using data from the O'Brien 2020 paper that was      16 unpublished, correct?      17 A Again, from the NHS I cohort that was not      18 published.      19 Q That's right. Thank you.      20 You then report in this footnote that (as      21 read): "We included data on women with intact fallopian      22 tubes," correct?      23 A Yes.      24 Q And then you make the statement after that "to      25 harmonize with other publications," correct?</p>	<p style="text-align: right;">Page 69</p> <p>1 MR. HEGARTY: Okay. That's what I meant.      2 Q Did you -- when I -- when I asked that      3 question, I meant the Nurses' Health Study data.      4 Did -- so same question, making reference to      5 the Nurses' Health Study data.      6 A I think many of the studies adjusted in the      7 multivariate analysis for whether or not the tubes were      8 patent or not patent. In the O'Brien study, that wasn't      9 an available adjustment. So most consistent to get at      10 the question, which is does talcum powder cause ovarian      11 cancer, to be consistent with the intent of those other      12 papers, which is to account for patent tubes, I believe      13 choosing the representation of the cohort who had patent      14 tubes made the most sense in terms of consistency.      15 Q Do you agree, though, that there -- to the      16 extent that you're comparing a set of data with -- of      17 women with intact fallopian tubes to a set of data that      18 didn't distinguish it and, therefore, would include      19 women with intact and with not intact fallopian tubes,      20 there could be some inconsistency?      21 A I think there was an adjustment for that, but      22 the degree that the results are not stratified, which I      23 think is what you're getting at, presented separately, I      24 think there is not perfect consistency on that issue      25 where everyone was with open tubes or not.</p>

Page 70	Page 72
<p>1 Q Did you have all the Nurses' Health Study data 2 that included women with and without intact tubes?</p> <p>3 MS. O'DELL: Object to the form.</p> <p>4 THE WITNESS: We did have results on all 5 women.</p> <p>6 BY MR. HEGARTY:</p> <p>7 Q Could you have included all women in this 8 analysis?</p> <p>9 A Yes, we could have.</p> <p>10 Q Did you do that and -- and see if it made a 11 difference?</p> <p>12 A At the time of doing the study, we had not 13 done that, but I saw that that was raised by you guys, 14 and when I saw that, I thought that was a valid point to 15 evaluate, and at that point I did reach out, I think, in 16 December to ask the biostatistician to do a sensitivity 17 analysis to evaluate the impact had we made that other 18 decision.</p> <p>19 Q Who is the biostatistician you reached out to?</p> <p>20 A The same. Lazar.</p> <p>21 Q Has that sensitivity analysis been done?</p> <p>22 A Yes.</p> <p>23 Q Do you have documentation of that sensitivity 24 analysis?</p> <p>25 A Yes.</p>	<p>1 that -- the email we were provided as the next exhibit, 2 which is Exhibit --</p> <p>3 MS. FLAGEOLLET: Six.</p> <p>4 MR. HEGARTY: -- 6.</p> <p>5 (Exhibit 6 was marked for identification by 6 the court reporter.)</p> <p>7 THE WITNESS: Thank you.</p> <p>8 MR. HEGARTY: So I've marked, as Exhibit No. 9 6, a document we were provided prior to the deposition.</p> <p>10 Q Can you tell me what this document is, what 11 Exhibit 6 is?</p> <p>12 A Yes.</p> <p>13 I reached out to the biostatistician on the 14 Woolen paper to ask her a sensitivity analysis if she 15 would recalculate the overall results by using the 16 number from the Nurses' Health Study of all women rather 17 than those with open fallopian tubes.</p> <p>18 Q Is this the only document that you have 19 reporting on that sensitivity analysis?</p> <p>20 A Yes.</p> <p>21 Q Would Dr. Lazar have -- based on how you 22 understand she works, have additional documents that 23 would reflect the sensitivity analysis that she did?</p> <p>24 A I suspect she could have some SAS programming 25 code, but -- but that would be all.</p>
Page 71	Page 73
<p>1 Q Is that something you brought with you today?</p> <p>2 A I think we sent it to you. I think it's one 3 of those documents that was recently shared. I was 4 given these results about a week ago or so by Ann, and I 5 forwarded them to the lawyers.</p> <p>6 MS. O'DELL: And they were provided.</p> <p>7 MR. HEGARTY: Is that in the email?</p> <p>8 MS. O'DELL: Yes. It was provided in keeping 9 with the requirements for disclosure, and they were 10 actually put in early, was Saturday, and it was in the 11 DropBox that was provided to you.</p> <p>12 MR. HEGARTY: Understood. My question is more 13 specific than that.</p> <p>14 Is that in the email that -- that was provided 15 in that DropBox?</p> <p>16 MS. O'DELL: Correct. I can represent -- she 17 doesn't know what's in the DropBox. I'll represent that 18 it was in the DropBox.</p> <p>19 MR. HEGARTY: I will go ahead and show you a 20 copy of that email that we were provided. It should be 21 just a single page. Did we not get it?</p> <p>22 MS. O'DELL: I'm happy to provide a -- a copy 23 if you want to mark it.</p> <p>24 MR. HEGARTY: We may not have gotten a copy 25 that -- oh, wait. We got it. We got it. We'll mark</p>	<p>1 Q The SAS programming code wouldn't be something 2 -- would that be something you could print out that 3 would show the data input and the results she got from 4 the sensitivity analysis?</p> <p>5 A I'm going to have to say I don't know the 6 answer to that. There's probably some -- some 7 documentation of her code.</p> <p>8 Q What were the results when she -- let me back 9 up again.</p> <p>10 So what she did was do the same study analysis 11 but included the entirety of the Nurses' Health Study 12 women with and without patent tubes?</p> <p>13 A That's correct.</p> <p>14 Q What did she find when she did that 15 sensitivity -- sensitivity analysis?</p> <p>16 A And I should say she included about four 17 sensitivity analyses in the published paper where we 18 included all those results as supplemental materials.</p> <p>19 For this sensitivity, she basically swapped 20 out the numbers for O'Brien's NHS I data for all women 21 versus just with patent tubes, and the impact was very 22 small on the overall estimate. The overall estimate had 23 a point estimate of 1.47 with a confidence interval of 24 about 1.35 to 1.68. When she swapped it out, the point 25 estimate was 1.41 with a confidence interval of 1.24 to</p>

<p style="text-align: right;">Page 74</p> <p>1 1.64, so a very small change.</p> <p>2 Q Okay. You can put that aside. We may -- we</p> <p>3 may come back to it.</p> <p>4 Had you thought about doing that sensitivity</p> <p>5 analysis since you -- before you had read some -- or</p> <p>6 understood there was some commentary about the use of</p> <p>7 patent versus tot- -- the tot- -- patent women versus</p> <p>8 the totality of women?</p> <p>9 MS. O'DELL: Object to the form.</p> <p>10 You may answer.</p> <p>11 THE WITNESS: Had I thought of it, we would</p> <p>12 have done it. I didn't think of it. I thought it was a</p> <p>13 -- a valid question that was raised by -- by your team.</p> <p>14 BY MR. HEGARTY:</p> <p>15 Q Turning over to the next page of the Woolen</p> <p>16 paper, the page that includes the discussion part of it,</p> <p>17 you took it -- you mentioned you did several sensitivity</p> <p>18 analysis [sic] that included running -- running the</p> <p>19 analysis without the Wu paper, correct? The Wu data, I</p> <p>20 should say. And I'm looking at the top left-hand side</p> <p>21 of the page with a discussion on it on the --</p> <p>22 A Yes.</p> <p>23 Q -- right-hand column.</p> <p>24 A Yes, we did. Yes, we did.</p> <p>25 Q Did you also do that same sensitivity analysis</p>	<p style="text-align: right;">Page 76</p> <p>1 That was a true statement in 2022, correct?</p> <p>2 A Yes.</p> <p>3 Q That's still a true statement, correct?</p> <p>4 A I think we've made a lot of progress in</p> <p>5 understanding the mechanism since then. So I think the</p> <p>6 statement's true in that we don't know the precise</p> <p>7 mechanism, but we have a lot more supporting evidence of</p> <p>8 how it happens than we did at the time of this</p> <p>9 publication.</p> <p>10 Q Talking generally about your paper as it</p> <p>11 relates to frequency, you actually state in your amended</p> <p>12 report, as you had stated previously, that with regard</p> <p>13 to the Gertig study, that -- you say a potential</p> <p>14 weakness of the Gertig study was that frequency but not</p> <p>15 duration was measured so that clear lifetime exposure</p> <p>16 was missing.</p> <p>17 That statement applies to your study as well,</p> <p>18 right?</p> <p>19 A I think that statement suggests that it would</p> <p>20 be good to have a combination of frequency and duration.</p> <p>21 I don't think one invalidates the other, but it would be</p> <p>22 better, particularly in a cohort study where you have</p> <p>23 the opportunity to ask questions as broadly as possible,</p> <p>24 for them to have added that other question.</p> <p>25 Q But my question, though, is: As -- as it</p>
<p style="text-align: right;">Page 75</p> <p>1 excluding the Schildkraut data?</p> <p>2 A I believe we did, but let me see if I can find</p> <p>3 it.</p> <p>4 MS. O'DELL: If you need the supplemental</p> <p>5 tables, Doctor, just let us know.</p> <p>6 MR. HEGARTY: They should be at the back of</p> <p>7 that copy.</p> <p>8 MS. O'DELL: Okay.</p> <p>9 THE WITNESS: I -- I don't -- I don't see that</p> <p>10 we did that, but --</p> <p>11 BY MR. HEGARTY:</p> <p>12 Q The reason I ask about Schildkraut was that</p> <p>13 their definition -- that paper's definition of body</p> <p>14 powder included cornstarches, correct?</p> <p>15 A I believe it -- I believe it did.</p> <p>16 Q Did you consider doing a sensitivity analysis</p> <p>17 without Schildkraut because of the way they define body</p> <p>18 powder use?</p> <p>19 A The fact that we didn't do that sensitivity</p> <p>20 analysis suggests that we didn't think about doing that</p> <p>21 sensitivity analysis.</p> <p>22 Q Looking over in the "DISCUSSION" section, the</p> <p>23 second paragraph, the first line says: "The precise</p> <p>24 mechanism whereby talcum powder causes ovarian cancer is</p> <p>25 not fully understood."</p>	<p style="text-align: right;">Page 77</p> <p>1 relates to the statements you made about Gertig and it</p> <p>2 only reporting on frequency of data as a potential</p> <p>3 weakness, that applies to your paper too?</p> <p>4 MS. O'DELL: Object to the form.</p> <p>5 BY MR. HEGARTY:</p> <p>6 Q In other words, what would be the difference</p> <p>7 in between how you characterize your reporting of</p> <p>8 frequency versus how Gertig characterized its reporting</p> <p>9 of frequency? And that's referring to the 2000 paper.</p> <p>10 A I think in my criticism of the published work,</p> <p>11 I was talking about broadly how these papers contribute</p> <p>12 to our knowledge and how they could have been better.</p> <p>13 And so I think it doesn't invalidate what they report on</p> <p>14 frequency, which is important, but it would have also</p> <p>15 been good if they gave us a combined frequency and</p> <p>16 duration. That would have been even better.</p> <p>17 In our review, some of the contributing papers</p> <p>18 did do frequency and duration, which was even better. I</p> <p>19 don't think it invalidates any results about frequency.</p> <p>20 It's just saying it would be better to have more detail</p> <p>21 than -- I don't think I levied those criticisms lightly.</p> <p>22 It was a cohort study that should have asked that from</p> <p>23 the very beginning.</p> <p>24 Q So your comment about it would have been</p> <p>25 better would apply to your paper too, right?</p>

1 A The -- the criticisms of a systematic review 2 were different. I didn't have a capacity to tell the 3 investigators what to ask. I was just pooling what they 4 did ask, and so you wouldn't consider that a criticism 5 of a systematic review. You pool what's been published, 6 and what's been published is reliably on frequency and 7 not duration. So I wouldn't levy that against our -- 8 our paper.  9 Q If you look at the "Strengths and Limitations" 10 section, you actually say in the first line that "The 11 primary strength of our study is our focus on frequent 12 users of perineal talcum powder," correct?  13 A I believe you, but I'm not sure --  14 Q Sure.  15 A -- where I say that.  16 Q Look at the "Strengths and Limitations" 17 section --  18 A Oh.  19 Q -- the heading "Strengths and Limitations" -- 20 A Oh, yes. Yes.  21 Q -- and the first line under that.  22 A Yes.  23 Q The first line under the "Strengths and 24 Limitations" section says: "The primary strength of our 25 study is our focus on frequent users of perineal talcum	Page 78  1 the "Conflict of Interest" section. Tell me when you're 2 there. 3 A Yes. 4 Q You disclosed that you have served as a paid 5 expert witness for the plaintiffs in the talcum powder 6 litigation, correct? 7 A Yes. 8 Q You agree that it's important for the reader 9 of your Woolen 2022 paper to know that, correct? 10 A Yes. 11 Q That -- so that a reader could evaluate 12 whether there's a conflict of interest that you have as 13 it relates to the results of this paper in relation to 14 your work in the talc litigation, correct? 15 A Yes. 16 Q You can put that paper aside. 17 I want to talk for now -- let me start over 18 again. 19 I want to talk more -- in more detail about 20 your Second Amended Expert Report. So if you could have 21 that with you. 22 A I do have that. I'm just checking the time, 23 and I'm going to have to go to the bathroom -- 24 Q Okay. 25 A -- before we get to the end, if this is a good
Page 79  1 powder," correct? 2 A Yes. 3 Q That would then also -- that should also apply 4 is -- in other words, that same statement should apply 5 to the Gertig 2000 paper, right? 6 MS. O'DELL: Object to the form. 7 THE WITNESS: I'm not sure what you're asking. 8 BY MR. HEGARTY: 9 Q Well, Gertig also focused on frequency of 10 perineal talcum powder use, correct? 11 A Yes. 12 Q That would also mean that that's a primary 13 strength of that study, just as you say focusing on 14 frequency is a primary strength of your study, correct? 15 MS. O'DELL: Object to the form. 16 THE WITNESS: I think -- I mean, the primary 17 strength of the Gertig study is it's a large cohort 18 study that followed women for decades. That's the 19 primary strength of that study. 20 To address the importance of what -- whether 21 talcum powder is a risk factor, you need to assess 22 frequency, and I think they did that, so I think that is 23 a strength of the study. 24 BY MR. HEGARTY: 25 Q Turning over to the last page of your study,	Page 81  1 break. 2 MR. HEGARTY: It's a good break because we're 3 switching to -- to the -- another document -- 4 THE WITNESS: Perfect. 5 MR. HEGARTY: -- so let's go ahead and take 6 that break. 7 THE WITNESS: Great. 8 (Recess.) 9 MR. HEGARTY: We are back on the record. 10 Q I have one other question as it relates to 11 Exhibit No. 6. It's the email Dr. Lazar to you dated 12 March 4, 2024. 13 Do you still have that exhibit in front of 14 you, Doctor? 15 A I do. 16 Q Can you explain to me what -- if you can, what 17 Dr. Lazar is talking about in the first paragraph? 18 A Yes. 19 She's saying to generate the graphs that we 20 used in the manuscript -- and she generated those graphs 21 for each of the sensitivity analysis [sic] -- that the 22 program she's using, STATA, she's not sure what happens 23 when she generates the graphs. The confidence intervals 24 are coming out wrong. So she said if I want the graphs, 25 she will dig in and figure it out, but, otherwise, the

<p>1 point estimate she just used with SAS. SAS is      2 notoriously not good with graphs.      3 Q Had you responded to this email that is the      4 March 4, 2024, email?      5 A It seems likely that I did.      6 MR. HEGARTY: Can we get a copy of that email?      7 We'll follow up on it.      8 MS. O'DELL: (Nods head.)      9 BY MR. HEGARTY:      10 Q Do you remember what you -- what your      11 follow-up was?      12 A I'm going to guess I said, "Thanks. This is      13 great. Don't need the graphs."      14 Q You're saying here today you don't need the      15 graphs.      16 Why don't you need the graphs?      17 A The change -- there's nothing I would do with      18 those graphs. I wanted to know the impact on the      19 results. She's giving me the impact on the results.      20 The graphs don't inform that at all. That would just be      21 if I was publishing them, and we're not publishing them.      22 There's no -- there's nothing to them to publish.      23 Q To know what is happening with the -- the      24 graphs with this new analysis, that is, the specifics of      25 it, we'd have to talk to Dr. Lazar; is that correct?</p>	<p>Page 82</p> <p>1 and fragrances may all play a role."      2 Do you see where I'm reading?      3 A I do.      4 Q Now, you say they "may all play a role."      5 Which of these substances, in your opinion, to      6 a reasonable degree of medical or scientific certainty,      7 do play a role in talcum powder use causing ovarian      8 cancer?      9 A I think the evidence that I have looked at the      10 most closely is asbestosiform talc and asbestos. I know      11 less about the etiology and the mechanism of how heavy      12 metals and fragrances may play a role. Nonetheless, in      13 reading about the harmful effects of those in IARC      14 reports, they have a role in carcinogenesis. I just      15 have seen less detailed mechanistic evidence related to      16 those.      17 Q Can you quantify the role of asbestosiform talc      18 and asbestos in talcum powder use causing ovarian      19 cancer?      20 MS. O'DELL: Object to the form.      21 You may answer.      22 THE WITNESS: I believe strongly that those      23 ingredients in talcum powder products causes the ovarian      24 cancer.      25 MR. HEGARTY: When I say "quantify," let me be</p>
<p>1 MS. O'DELL: Object to the form.      2 THE WITNESS: You mean what's wrong with the      3 software?      4 BY MR. HEGARTY:      5 Q Or what she's seeing when she's doing the      6 software, what she's running it. You would -- she would      7 have those details and not you, correct?      8 A That's correct.      9 Q You can put that aside.      10 So now we're talking about Exhibit No. 1, I      11 believe, which is your Second Amended Expert Report.      12 Is that, indeed, Exhibit No. 1?      13 MS. O'DELL: It's 2.      14 MR. HEGARTY: Two. I'm sorry.      15 Q So now we're going to talk about in more      16 detail Exhibit No. 2, your second amended report.      17 If you could first turn to page 4 just before      18 the paragraph -- I'm sorry. I need to back up.      19 Page 4, four lines down from the top. Tell me      20 when you're on page 4.      21 A I'm there.      22 Q There's a line you added after the phrase "nor      23 does it confirm the specific component in talcum powder      24 products that make them carcinogenic." You added:      25 "- asbestosiform talc, platy talc, asbestos, heavy metals,</p>	<p>Page 83</p> <p>1 more clear.      2 Q Are you able to assign a percentage of their      3 contribution or other -- in other- -- or otherwise      4 quantify in some numerical fashion the extent of their      5 contribution as it relates to -- as compared to platy      6 talc versus heavy -- heavy metals, fragrances and      7 everything else in -- as alleged in -- as is in talcum      8 powder?      9 A The epidemiology describes the exposure.      10 That's the -- that's the cause of avagia [phonetic]. In      11 terms of guessing which of the components numerically, I      12 think it's mostly the asbestos and the asbestosiform talc,      13 but I don't have a way to attach a numerical number      14 there.      15 Q Have you developed any new or additional      16 expertise on asbestos and ovarian cancer since your      17 October 2021 deposition?      18 A I've read a lot more papers since then about      19 the few lines of evidence that I think are important,      20 the mechanism, both basic science and different sort of      21 cellular studies that have shown the impact of asbestos      22 and talc and on ovarian cell lines and ovarian cancer.      23 So I've read a number of papers about that that I cite      24 in this report.      25 And then I've seen a good amount of testing</p>

22 (Pages 82 - 85)

<p style="text-align: right;">Page 150</p> <p>1 Q This falls into category two, correct?</p> <p>2 A I'm going to trust you, but it sounds about</p> <p>3 right. I --</p> <p>4 MS. O'DELL: Easy --</p> <p>5 BY MR. HEGARTY:</p> <p>6 Q It requires an annual report, right?</p> <p>7 A It's definitely an annual report.</p> <p>8 Q In each of the years you've served as an</p> <p>9 expert witness for Plaintiffs in this litigation, have</p> <p>10 you filled out an annual report disclosing that work?</p> <p>11 A I have.</p> <p>12 Q And have you provided all the information that</p> <p>13 was requested in that report?</p> <p>14 A It's -- the reports at the University of</p> <p>15 California are very explicit. I have to give an amount</p> <p>16 of money for what work, any paid travel, all of that.</p> <p>17 That's been disclosed every year.</p> <p>18 Q And do you still have copies of those forms</p> <p>19 that you submitted as part of that policy?</p> <p>20 A They're kept as a running total. So I don't</p> <p>21 possess them, but they're online, and I can go through</p> <p>22 the 50-such reports I filed over the last ten years.</p> <p>23 MR. HEGARTY: And we will follow up, and we'll</p> <p>24 make a request for those documents. You don't have to</p> <p>25 decide about it now, but I'm just giving you a heads-up.</p>	<p style="text-align: right;">Page 152</p> <p>1 THE WITNESS: I mean, I remember wanting to go</p> <p>2 through the individual studies in more detail this time,</p> <p>3 but I don't remember what -- what led me to want to do</p> <p>4 that. I don't remember what the report said before.</p> <p>5 BY MR. HEGARTY:</p> <p>6 Q Well, with regard to the statements you made</p> <p>7 in your prior reports, is there any uncertainty that you</p> <p>8 would stand behind those statements still here today?</p> <p>9 A I don't know what those statements are. If --</p> <p>10 if there was an error that I cited one study as showing</p> <p>11 a dose report and it didn't and I corrected it in this</p> <p>12 report, then I would stand by this report and</p> <p>13 acknowledge I made a mistake.</p> <p>14 If I said something in the prior report that</p> <p>15 was important to know how I changed my view, I'd need to</p> <p>16 know what it was to know how I changed it. I don't</p> <p>17 remember a meaningful change in my position on dose</p> <p>18 report [sic].</p> <p>19 Q The -- the Woolen 2022 paper did not look at</p> <p>20 dose response, correct?</p> <p>21 A I think, taken into context, the Woolen</p> <p>22 contributes a great deal to dose response. So if you --</p> <p>23 if you look at the other systematic reviews, like Taher</p> <p>24 and Penninkilampi that looked at any exposure, there are</p> <p>25 several systematic reviews, and they have point</p>
<p style="text-align: right;">Page 151</p> <p>1 MS. O'DELL: Yeah. And we'll just tell you</p> <p>2 we'll object, and we'll talk about it later.</p> <p>3 MR. HEGARTY: Okay. I'll make a request, but</p> <p>4 we'll follow up.</p> <p>5 Q If you would turn, next, over to page 35 of</p> <p>6 your report.</p> <p>7 You revised the dose response section between</p> <p>8 this report and your prior report.</p> <p>9 Do you stand behind the statement you</p> <p>10 previously made in the -- in your reports about dose</p> <p>11 response?</p> <p>12 A Can you be more explicit about what -- what</p> <p>13 statements? I'm guessing I stand by it, but I don't</p> <p>14 know what statements.</p> <p>15 Q Well, let me just ask it separately.</p> <p>16 With regard to your prior statements as it</p> <p>17 relates to dose response in your initial report and your</p> <p>18 first amended report, do you stand by those statements?</p> <p>19 A I'd have to see what those statements were.</p> <p>20 MS. O'DELL: Can I just make an objection.</p> <p>21 Objection to the form to the degree it's vague</p> <p>22 and it's calling her to make detailed analysis of</p> <p>23 something that's not in front of her.</p> <p>24 But to the degree you remember and can</p> <p>25 respond, please do so.</p>	<p style="text-align: right;">Page 153</p> <p>1 estimates of 1.28 to 1.35 with any use, and then Woolen</p> <p>2 shows multiple, and the point estimate is higher, 1.47.</p> <p>3 I think that shows strong evidence of dose response even</p> <p>4 though within the paper itself it didn't evaluate the</p> <p>5 dose response.</p> <p>6 MR. HEGARTY: The next paper I want to mark as</p> <p>7 an exhibit is a paper you referenced that you had read</p> <p>8 earlier or that your counsel had referenced that you</p> <p>9 read earlier, a 2024 paper by Chang. This is going to</p> <p>10 be marked as an exhibit.</p> <p>11 MS. O'DELL: Make sure it's in your binder.</p> <p>12 THE WITNESS: Is that the one?</p> <p>13 MS. O'DELL: It could be. I'm not sure.</p> <p>14 MR. HEGARTY: That is Exhibit, what, 13?</p> <p>15 MS. FLAGEOLLET: Yeah.</p> <p>16 (Exhibit 13 was marked for identification by</p> <p>17 the court reporter.)</p> <p>18 BY MR. HEGARTY:</p> <p>19 Q Do you have any comments with respect to this</p> <p>20 paper that you would add to your November 2023 report?</p> <p>21 MS. O'DELL: Object to the form in the sense</p> <p>22 that she didn't comment on it in her November 2023</p> <p>23 report. So you -- I'm not sure what you're asking her.</p> <p>24 BY MR. HEGARTY:</p> <p>25 Q Did you understand my question?</p>

39 (Pages 150 - 153)

<p style="text-align: right;">Page 174</p> <p>1       MR. HEGARTY: We have also -- you also      2 provided to you [sic] notes in a red book that you've      3 shown me, and we're going to designate those notes that      4 were created since October 2021 as it relates to your --      5 your work in the talcum powder litigation as Exhibit No.      6 21.</p> <p>7       (Exhibit 21 was marked for identification by      8 the court reporter.)</p> <p>9       MR. HEGARTY: And we'll not go ahead and mark      10 those now, but we'll designate those and copy those as      11 an exhibit to the transcript.</p> <p>12       MS. O'DELL: So we'll get those scanned and      13 provide them to the court reporter.</p> <p>14 BY MR. HEGARTY:</p> <p>15      Q You mentioned that you have looked at -- or      16 looked at or received additional reports from other      17 experts since your October 2021 deposition.</p> <p>18       Have you had any communication with any expert      19 that you understood or understand is an expert for      20 Plaintiffs in the MDL litigation since October 2021?</p> <p>21      A I have not.</p> <p>22      Q You brought with you three notebooks, or is it      23 two notebooks?</p> <p>24      A Three.</p> <p>25      Q Three notebooks. I will designate those</p>	<p style="text-align: right;">Page 176</p> <p>1       Q First, looking at Exhibit 2023 -- I'm sorry --      2 Exhibit 23, these are comments you received as part of      3 the rejection by the Annals of Internal Medicine,      4 correct?</p> <p>5       A They're definitely -- they're definitely      6 comments. I think if they were together with this      7 cover, then they're -- then they're -- then they're      8 those comments from Annals of Internal Medicine.</p> <p>9       Q This is a document you've seen before?</p> <p>10      A I've seen this document, but I've just      11 realized that -- did these two documents come together?</p> <p>12      Q No. They are separate documents. They are      13 not related.</p> <p>14      A Okay. I think they are Annals of Internal      15 Medicine comments, but ...</p> <p>16      Q This was part -- this -- these were received      17 as part of the -- that journal rejecting your Woolen      18 2022 paper?</p> <p>19      A I think that's what you asked for, yes.</p> <p>20      Q And it specifically refers in this -- these      21 comments to lines -- and did you receive a lined      22 manuscript in conn- -- in addition to these comments?</p> <p>23      MS. O'DELL: Objection to the form.</p> <p>24      THE WITNESS: I don't believe I did. I think      25 I got these comments through Dr. Woolen forwarding me</p>
<p style="text-align: right;">Page 175</p> <p>1 notebooks as Exhibit 22. And we'll make arrangements to      2 copy those, and those notebooks are a literature      3 notebook, a -- a report and testimony notebook. And      4 remind me what the third notebook is.</p> <p>5      A And my -- my own depositions.</p> <p>6      Q Your own depositions. Thank you.</p> <p>7       Let's go off the record real quick.</p> <p>8       (Discussion Off the Record.)</p> <p>9       (Exhibit 22, Exhibit 23, and Exhibit 24 were      10 marked for identification by the court      11 reporter.)</p> <p>12      MR. HEGARTY: We can go back on the record.</p> <p>13      The next documents I've marked as Exhibits      14 23 and 24 are additional documents produced since      15 October 2021. And those are reviewer comments from the      16 Annals of Internal Medicine and then the February 15,      17 2021, letter to Dr. Woolen from Dr. Chang regarding the      18 acceptance of your paper.</p> <p>19      THE WITNESS: Yep.</p> <p>20      MS. O'DELL: Give me just a second.</p> <p>21      MR. HEGARTY: Let's go ahead and go off the      22 record.</p> <p>23       (Discussion Off the Record.)</p> <p>24      MR. HEGARTY: Okay. Let's go back on the      25 record.</p>	<p style="text-align: right;">Page 177</p> <p>1 the comments, but not the actual document.</p> <p>2 BY MR. HEGARTY:</p> <p>3      Q Looking at the first comment, lines 132 to      4 137, second line, it says (as read): "It's unclear      5 whether studies that examined talcum powder applications      6 from both the perineum and 'other' sites/used were      7 excluded [sic] or excluded."</p> <p>8       What's the answer to that?</p> <p>9      A So in the paper, we extracted information that      10 described perineal exposure, ignoring the other site.      11 So we didn't extract information for underarm exposure,      12 but if it was any genital exposure, that's what we took,      13 ignoring the other exposures.</p> <p>14      Q The next paragraph below says (as read):      15 "They defined genital use as 'including on underwear or      16 sanitary napkins'" -- this is in reference to the      17 Schildkraut study.</p> <p>18      A Yes.</p> <p>19      Q -- "or on birth control devices like      20 diaphragms," which was apparently excluded from this      21 analy- -- meta-analysis."</p> <p>22       Is that correct?</p> <p>23      A We excluded exposures that were only      24 diaphragmatic exposure, as opposed to if there was      25 genital exposure that also had other exposures, we kept</p>

45 (Pages 174 - 177)

Golkow Technologies,

A Veritext Division

877-370-3377

www.veritext.com

<p style="text-align: right;">Page 178</p> <p>1 them in with the understanding that there were a small      2 percent of patients who may have had just sanitary      3 napkin exposure, but if it was just diaphragm, we didn't      4 include it. If it was perineal exposure plus the      5 Schildkraut included these other exposures, they were      6 included.</p> <p>7 Q Looking at paragraph 3, lines 163 to 164, I      8 believe you answered this earlier, that the reference      9 group was nonusers of talcum powder, correct?</p> <p>10 A As line 163 to 164?</p> <p>11 Q Yes.</p> <p>12 A Yes.</p> <p>13 Q Line four -- or paragraph 4 says (as read):      14 "Since the OR and RR are equal only when there is no      15 effect, is it appropriate to combine them?"</p> <p>16 Is that -- is it appropriate to combine them?</p> <p>17 A I mean, this question is: How can you compare      18 case control studies and cohort studies?</p> <p>19 And yes, I think it's appropriate to combine      20 them.</p> <p>21 Q Looking at paragraph 5, it purported to      22 identify an error where the number of women reported      23 with ovarian cancer was 2,000 -- 204,377.</p> <p>24 Was that correct?</p> <p>25 A They're -- they're saying that an earlier</p>	<p style="text-align: right;">Page 180</p> <p>1 it was an important bias.</p> <p>2 Q Looking down under reviewer No. 2's comments,      3 it -- in particular the paragraph that reads -- that      4 starts: "Misclassification of talc."</p> <p>5 A Yes.</p> <p>6 Q It says (as read): "Misclassification of talc      7 as an IARC Group 1 carcinogen." Then it refers to lines      8 92 and 94. It goes on to say (as read): "Talc-based      9 body power -- based body powder (perineal use of) should      10 be classified -- should be correctly classified as      11 'possibly carcinogenic to humans (carcinogen group 2B)',      12 as per -- per IARC."</p> <p>13 Is that correct?</p> <p>14 A That's a very incorrect statement, but one      15 that others have shared. IARC considers talc-based      16 products that have asbestos talc as being a group 1      17 carcinogen.</p> <p>18 Q The next line reads: "According to the IARC      19 asbestos and talc containing asbestos fibers are      20 classified as group 1 carcinogens, but perineal --      21 perineal use of talc-based" body "powder is not."</p> <p>22 Do you agree with that statement?</p> <p>23 A I strongly disagree with that statement.</p> <p>24 Q For reasons you've told me about already?</p> <p>25 A Yes.</p>
<p style="text-align: right;">Page 179</p> <p>1 draft we listed the number of person years of follow-up,      2 which is the number of people times the number of years      3 as subjects, and that's wildly off, yes. I don't see      4 that draft in any other paper, but this was an obvious      5 error.</p> <p>6 Q Turning to the next page --</p> <p>7 A In the -- in our old draft, not in the -- not      8 in the published manuscript.</p> <p>9 Q Turn to the next page, paragraph 7, lines 260      10 to 262. It says (as read): "Differential recall by      11 cases versus controls is an important concern in      12 case-control studies."</p> <p>13 Do you agree with that statement?</p> <p>14 A I think it's a -- it's an important potential      15 control -- a -- an important potential concern.</p> <p>16 Q And do you see where they raise the issue of      17 including -- or any reference -- let me start over      18 again.</p> <p>19 It goes on to say (as read): "Do you have any      20 references to support your claim that recall bias is      21 unlikely to have made much of an effect on the studies      22 included in this meta-analysis?"</p> <p>23 Did you put such -- any such reference in the      24 paper itself?</p> <p>25 A We did, and we explained why we didn't think</p>	<p style="text-align: right;">Page 181</p> <p>1 Q The next paragraph says: "In the Results and      2 Discussion, an explanation for the exclusion of duration      3 and cumulative talc exposure should be included."</p> <p>4 Did you provide an explanation in your Woolen      5 2022 paper?</p> <p>6 A We did not. This is saying you should have      7 done a different topic, and that's not something usually      8 included in a paper that -- why we chose not to do a      9 different topic.</p> <p>10 Q The next paragraph says that at least the      11 draft they read states (as read): "Recall bias on these      12 studies is unlikely to be meaningful given publicity      13 related to talc did not exist at the time these studies      14 was completed."</p> <p>15 Recall bias is not dependent upon publicity of      16 an exposure versus an outcome, correct?</p> <p>17 A I would disagree with that. There's -- you      18 only misremember something if you think it's important.      19 So you misremember your smoking if you have lung cancer      20 because you know how important it is. But there's no      21 reason to misremember something that has no material      22 difference. So I think it's -- I think the publicity      23 would be a potential reason to misremember, where you      24 know that's supposed to be harmful, and so you are more      25 likely to remember that if you have the disease.</p>

46 (Pages 178 - 181)

Golkow Technologies,

A Veritext Division

877-370-3377

www.veritext.com

<p style="text-align: right;">Page 182</p> <p>1 Q Asking in a different way, though: Recall      2 bias isn't just exclusive to those exposures that have      3 been publicized, correct?</p> <p>4 A I think the issue with recall bias is a      5 differential remembering between cases and not cases.</p> <p>6 So if you're saying that everyone misremembers      7 all the time, that is true. But if it's a differential      8 misremembering, that's important to the study, and so      9 the differential misremembering would be related to an      10 exposure or a beneficial exposure that you want to      11 remember. Like mammography, if you have breast cancer,      12 there's very differential remembering because women      13 attribute a -- a importance to that. If there's nothing      14 important about it, then there's misremembering equally      15 in the cases and control.</p> <p>16 Q Did you make any revisions to your manuscript      17 based on the reviewer comments that we marked as Exhibit      18 23?</p> <p>19 A Extensively.</p> <p>20 Q Looking at Exhibit No. 24 --</p> <p>21 A Twenty-four.</p> <p>22 Q -- that is the acceptance of your paper.</p> <p>23 Did you subsequently receive galley sheets?</p> <p>24 There's also a reference to -- in the second      25 paragraph of the email, to receiving a line numbered</p>	<p style="text-align: right;">Page 184</p> <p>1 Yeah, that should be 24, and this is 23.      2 Which -- which one have I not marked?</p> <p>3 THE WITNESS: I was responding to a different      4 one.</p> <p>5 MR. HEGARTY: Oh, let me see that.</p> <p>6 Okay. Let's go ahead and mark this one as the      7 next exhibit, Exhibit 25.</p> <p>8 (Exhibit 25 was marked for identification by      9 the court reporter.)</p> <p>10 BY MR. HEGARTY:</p> <p>11 Q Can you tell me what Exhibit 25 is?</p> <p>12 A Twenty-five is what you were just asking      13 about. That's the acceptance.</p> <p>14 Q But in terms of the Exhibit 24, there is a      15 reference in it to saying a copy of the line-numbered      16 version of the manuscript is attached hereto, and that's      17 what I asked you about before.</p> <p>18 A Okay.</p> <p>19 Q Did you ever receive that?</p> <p>20 A I did not.</p> <p>21 Q Did you ever see any galley sheets?</p> <p>22 A No.</p> <p>23 Q Can I have that one back real quick?</p> <p>24 A Yeah, this one is marked 25.</p> <p>25 MR. HEGARTY: Let's go ahead and go off the</p>
<p style="text-align: right;">Page 183</p> <p>1 version of your manuscript attached thereto.</p> <p>2 Do you have any of those kinds of documents?</p> <p>3 A No, this -- I forwarded this. This was from      4 Dr. Woolen, so he would have those.</p> <p>5 Q Thank you.</p> <p>6 MS. O'DELL: And this was Exhibit -- what      7 number was the exhibit? Because --</p> <p>8 THE WITNESS: Actually, it's not numbered.</p> <p>9 MR. HEGARTY: I thought it was -- I thought we      10 put 24 on it.</p> <p>11 THE WITNESS: I think I have this, but I don't      12 have a number on it.</p> <p>13 MR. HEGARTY: I think, yeah, the exhibit      14 number is there.</p> <p>15 THE WITNESS: Did I lose the exhibit number?</p> <p>16 MS. FLAGEOLLET: It should be 24.</p> <p>17 THE WITNESS: Oh, there it is. I'm sorry.</p> <p>18 MS. O'DELL: Actually, Exhibit 24 is a      19 February 15th, 2021, email.</p> <p>20 MR. HEGARTY: Right. That's what I was      21 talking about. And 23 was the Annals of Internal      22 Medicine comments.</p> <p>23 MS. O'DELL: Okay. So you have not marked      24 that? Okay. Excuse me.</p> <p>25 MR. HEGARTY: Which one have I not marked?</p>	<p style="text-align: right;">Page 185</p> <p>1 record.</p> <p>2 (Discussion Off the Record.)</p> <p>3 MR. HEGARTY: Okay. We are back on the      4 record.</p> <p>5 I want to start by looking back at Exhibit No.      6 24. I think I misidentified what that was based on my      7 questions.</p> <p>8 Q Exhibit 24 is a copy of an email to Dr. Woolen      9 from Ms. Chang where the Annals of Internal Medicine are      10 rejecting publication of the -- what became the Woolen      11 2022 paper, correct?</p> <p>12 A Mm-hmm.</p> <p>13 Q "Yes"?</p> <p>14 A Yes.</p> <p>15 Q And this is the email that forwarded the      16 reviewer comments that we talked about earlier, correct?</p> <p>17 A Yes.</p> <p>18 Q Did you consider resubmitting your paper to      19 the Annals of Internal Medicine after the revisions --      20 after revisions were made?</p> <p>21 A As opposed to taking their referral?</p> <p>22 Q Yes.</p> <p>23 A Again, I'm -- I'm trying to remember what      24 happened, but in general, this letter doesn't say they      25 didn't take it because of the flaws. They didn't take</p>

<p style="text-align: right;">Page 186</p> <p>1 it because it's less likely to influence clinical      2 practice, and so that letter wouldn't suggest that      3 fixing whatever flaws they identified would lead to it      4 having a better chance to change practice, so I --      5 reading this letter, we would not have resubmitted it.</p> <p>6 Q Okay. Thank you.</p> <p>7 Since October of 2021, your last deposition,      8 have you told any patient of yours that -- with ovarian      9 cancer that it was caused by use of talcum powder?</p> <p>10 A No.</p> <p>11 Q Since October of 2021, have you determined      12 that any patient's ovarian cancer was caused by either      13 use of talcum powder or exposure to asbestos?</p> <p>14 A No.</p> <p>15 Q Since October of 2021, have you told anyone to      16 stop using talcum powder?</p> <p>17 A Yes.</p> <p>18 Q Who have you told?</p> <p>19 A I tell friends all the time not to use talcum      20 powder, particularly friends who have grandchildren.</p> <p>21 Q Since October of 2021, have you communicated      22 with any scientific or medical organization with regard      23 to your opinions in this litigation?</p> <p>24 A I have not.</p> <p>25 Q In particular, have you communicated with FDA</p>	<p style="text-align: right;">Page 188</p> <p>1 Q Where has the NCI made that statement?</p> <p>2 A I can see if I can find it for you, but they      3 have a statement online that I think describes that.</p> <p>4 Q A statement online under what section of the      5 website or what part of the website?</p> <p>6 A I -- I can't remember exactly where I would      7 have found that.</p> <p>8 Q You said you could find it for me.</p> <p>9 What would you [sic] take to find it?</p> <p>10 A I can look in my documents.</p> <p>11 MR. HEGARTY: Okay. Let's go ahead and go off      12 the record.</p> <p>13 (Discussion Off the Record.)</p> <p>14 MR. HEGARTY: Okay. We can go back on the      15 record.</p> <p>16 We took a short break for Dr. Smith-Bindman to      17 find the statement she was thinking about as it relates      18 to NCI and whether talcum powder use can cause ovarian      19 cancer.</p> <p>20 Q In looking at your materials, what did you      21 find, Dr. Smith-Bindman?</p> <p>22 A It said asbestos causes ovarian cancer.</p> <p>23 Q Going back to my question: Are you aware of      24 any scientific or medical group in the United States,      25 since your last deposition, who has made the statement</p>
<p style="text-align: right;">Page 187</p> <p>1 or any other regulatory authority since October of 2021?</p> <p>2 A I have not.</p> <p>3 Q Have you communicated with any medical society      4 or organization about your opinions in this case since      5 October of 2021?</p> <p>6 A I have not.</p> <p>7 Q Since October of 2021, have you become aware      8 of any US scientific or medical group, entity,      9 organization who has made the statement that talc use      10 can cause ovarian cancer?</p> <p>11 MS. O'DELL: Object to the form. Vague.</p> <p>12 THE WITNESS: So you're excluding the      13 Canadian --</p> <p>14 MR. HEGARTY: Correct.</p> <p>15 THE WITNESS: -- report?</p> <p>16 BY MR. HEGARTY:</p> <p>17 Q I'm talking exclusively as to the United      18 States.</p> <p>19 A The NCI has a statement, I believe, on talcum      20 powder and ovarian cancer.</p> <p>21 Q My question was specifically whether -- that      22 you're aware of any US scientific or medical group has      23 made the statement that talcum powder use can cause      24 ovarian cancer.</p> <p>25 A I believe the NCI has made that statement.</p>	<p style="text-align: right;">Page 189</p> <p>1 that talc use can cause ovarian cancer?</p> <p>2 A No.</p> <p>3 Q Are you aware of anyone as of today, March 20,      4 2024, outside of witnesses hired by the plaintiffs in      5 this litigation, who has stated that talc use can cause      6 ovarian cancer?</p> <p>7 A I'm not sure I -- is that also in the United      8 States?</p> <p>9 Q No, it's worldwide.</p> <p>10 A So, I mean, I think IARC states that the use      11 of talcum powder can cause ovarian cancer.</p> <p>12 Q How about we limit it to an individual, not an      13 entity?</p> <p>14 A I think a lot of the mechanistic studies that      15 are shown on a cellular level get changes suggest that      16 talcum powder can cause ovarian cancer and this is a      17 mechanism by doing so.</p> <p>18 Q My question, though, is: As to individuals      19 who have made statements, are you aware of any      20 individuals who have made statements outside of experts      21 for Plaintiffs in this litigation?</p> <p>22 A And outside of publications?</p> <p>23 Q Outside of publications.</p> <p>24 A So public statements.</p> <p>25 No, I don't -- I'm not sure of something that</p>

<p style="text-align: right;">Page 194</p> <p>1 A Wait. Wait. Wait. The carryover.      2 Q The carryover paragraph.      3 A Top right?      4 Q In the top right corner on page 383.      5 Are you there with me?      6 A I am.      7 Q Right up here (indicating).      8 A "However, it is unclear"? That sentence?      9 Q Well, I'm not at the sentence yet. I want to      10 make sure we're -- you're focusing on the --      11 A They're not systematically different.      12 Q Okay. The sentence reads: "The observed      13 increase" --      14 Do you see where I'm reading?      15 A Yes. Next sentence, yeah.      16 Q (As read): "The observed increase in      17 self-reported genital talc use and follow-up" -- which      18 is just what we talked about -- "relative to enrollment      19 among ovarian cancer survivors may indicate recall bias      20 is present and potentially driving some of the      21 previously observed differences in effect estimates      22 between" the "studies collecting genital powder exposure      23 status retrospectively versus prospectively."      24 Did I read that correctly?      25 A You did.</p>	<p style="text-align: right;">Page 196</p> <p>1 Q You make reference in the left-hand column to      2 the -- O'Brien's reporting of women with patent tube      3 [sic] versus unpatent tubes.      4 Do you see that in the --      5 A In the "Strengths and Limitations"?</p> <p>6 Q No, in the section on the other side that      7 begins "The pooled odd [sic] ratio."      8 A Yes.      9 Q And there --      10 A Yes.      11 Q -- you refer to the differences between the      12 patent and the nonpatent findings, correct?      13 A Yes.      14 Q You've seen, before, an editorial by Gossett      15 as it relates to this article, correct?      16 A Yes.      17 MR. HEGARTY: I'm going to show you that      18 editorial that I'll mark as Exhibit 27.      19 (Exhibit 27 was marked for identification by      20 the court reporter.)      21 MS. O'DELL: Yeah, this has been marked      22 before, Mark.      23 MR. HEGARTY: Oh, I understand, but this is      24 now in reference to the statements made in this article.      25 MS. O'DELL: But you're going to ask her about</p>
<p style="text-align: right;">Page 195</p> <p>1 Q Do you agree with that statement?      2 A I would not agree that -- that -- they're      3 making a very large conclusion about a small difference.      4 Q Do you actually -- is it -- strike that.      5 Is it your opinion that this paper actually      6 supports your opinions in this case?      7 A I do.      8 Q And how does it support your opinions in this      9 case?      10 A It suggests that there's consistency in      11 reporting of talc use. Even though it's an imperfect      12 agreement, which is what you're pointing out, it's very      13 good agreement.      14 Q You can set that aside.      15 If you could take -- find your Woolen paper,      16 which I think is Exhibit 1 or 2.      17 Do you know what exhibit the Woolen paper is?      18 MS. O'DELL: I don't. She has her version in      19 front of her.      20 THE WITNESS: Yes.      21 MS. FLAGEOLLET: Three.      22 BY MR. HEGARTY:      23 Q Turn over to the page that has "Strengths and      24 Limitations." It's --      25 A Yep. I'm there.</p>	<p style="text-align: right;">Page 197</p> <p>1 this article.      2 MR. HEGARTY: Well, I'm just going to ask      3 her -- you probably want me to use my time on something      4 that's already been covered, so you should be happy with      5 it.      6 Q If you turn over to the second page, the      7 left-hand column --      8 MS. O'DELL: You got four minutes, so knock      9 yourself out.      10 MR. HEGARTY: I'm not sure about that part.      11 I've got -- I think I've got about six, but --      12 Q Dr. Gossett -- by the way, do you know her?      13 A I do know her.      14 Q She makes a statement, in essence, that      15 because there's -- that the P value for heterogeneity      16 comparing these groups is 1.5. Statistically, they're      17 no different.      18 Isn't that what she's saying in this      19 editorial?      20 MS. O'DELL: Are you -- are you pointing her      21 to a specific page?      22 MR. HEGARTY: Yeah, I'm pointing her to the      23 second page over in the left-hand column, the line that      24 reads (as read): "The fact that there are no      25 significant differences in the HRs in the patent and</p>

50 (Pages 194 - 197)

Golkow Technologies,

A Veritext Division

877-370-3377

www.veritext.com

<p style="text-align: right;">Page 206</p> <p>1 A Yes, you did.</p> <p>2 Q And, in fact, is that what you include in your report?</p> <p>3 A Yes.</p> <p>5 Q And you were asked a number of questions about this cell study, the Mandarino study, as well as Emi and others.</p> <p>8 As you've reviewed these cell studies that have considered the effect of talc on different cells and different cell lines, has the data been consistent -- generally consistent across studies?</p> <p>12 A Yeah.</p> <p>13 MR. HEGARTY: Objection to the form.</p> <p>14 THE WITNESS: Yes, it has.</p> <p>15 BY MS. O'DELL:</p> <p>16 Q I want to ask you to recall the series of questions that were posed by counsel regarding testing of talcum powder products in 2022.</p> <p>19 A Yes.</p> <p>20 Q Do you recall that?</p> <p>21 A I do.</p> <p>22 Q And maybe 2021 as -- as well.</p> <p>23 If -- if -- do you have any understanding of whether those tests included Johnson's Baby Powder?</p> <p>25 A I believe I was asked about tests that were</p>	<p style="text-align: right;">Page 208</p> <p>1 to find my copy of it. For some reason, it's hiding from me. Okay. I found it. Go ahead.</p> <p>3 BY MS. O'DELL:</p> <p>4 Q And -- and you were --</p> <p>5 MR. HEGARTY: What page again? I'm sorry.</p> <p>6 MS. O'DELL: We were -- in Woolen, we were on Table 2.</p> <p>8 MR. HEGARTY: Okay. Thank you.</p> <p>9 BY MS. O'DELL:</p> <p>10 Q And specifically, I want to direct your attention to line 5 --</p> <p>12 A Yes.</p> <p>13 Q -- and -- which is the Harlow 1992 --</p> <p>14 A Yes.</p> <p>15 Q -- paper.</p> <p>16 And you were asked a series of questions about the data that was extracted from the Harlow paper, and, if I recall, you, in response to questions, told counsel that the data that was extracted was from Harlow Table 2.</p> <p>21 MR. HEGARTY: Object to form.</p> <p>22 THE WITNESS: Yes.</p> <p>23 BY MS. O'DELL:</p> <p>24 Q And -- and -- and so, Doctor, I want to just ask you, first: Was the data that was included in the</p>
<p style="text-align: right;">Page 207</p> <p>1 more cosmetic in general that could have talcum powder rather than the specific testing that I think I was referring to, which is from a decade earlier.</p> <p>4 Q And if the testing that was done in 2022 by the FDA was testing of cosmetics like eye shadow and other cosmetics not including Johnson's Baby Powder or Shower to Shower, would that have limited relevance to your opinions in this case?</p> <p>9 MR. HEGARTY: Objection to the form.</p> <p>10 THE WITNESS: It's unrelated to the case.</p> <p>11 BY MS. O'DELL:</p> <p>12 Q Let me ask if you would take out your paper -- the Woolen paper, which was previously marked, I believe, as Exhibit 3. And -- and then, also, we -- in relation -- so you can compare them, we had a discussion about the Harlow 1992 paper.</p> <p>17 Do you recall that?</p> <p>18 A I do.</p> <p>19 Q And -- and to my memory, the Harlow paper was not marked; you just referred to it.</p> <p>21 A Yes.</p> <p>22 Q And so if you'll turn in the Woolen paper, Exhibit 3, to Table 2.</p> <p>24 MR. HEGARTY: Can you give me just a second, Leigh? I don't need to go off the record. I just need</p>	<p style="text-align: right;">Page 209</p> <p>1 Woolen study from the Harlow paper correct?</p> <p>2 A Yes, it was.</p> <p>3 Q And was the data that was extracted from the Harlow paper that was included to generate the point estimate that you report in the paper -- was that accurate?</p> <p>7 A Yes --</p> <p>8 MR. HEGARTY: Objection.</p> <p>9 THE WITNESS: -- that's correct.</p> <p>10 BY MS. O'DELL:</p> <p>11 Q And you -- you mentioned that, you know, it's referred to in Table 2 of Woolen the Harlow specification of talc exposure use is -- is referenced as greater-than-10,000-lifetime applications.</p> <p>15 A It does say that in the table.</p> <p>16 Q And -- and is that some- -- is that something you would change or leave as-is?</p> <p>18 MR. HEGARTY: Objection to the form.</p> <p>19 THE WITNESS: The data that were extracted from the paper reflect greater-than-30-times-a-week exposure, and it's characterized as greater-than-10,000-lifetime exposures, but I'd prefer it said greater than 30 times per month because that's what we actually extracted, but the description of it is -- is inaccurate. The abstracted data is completely</p>

1 accurate. 2 BY MS. O'DELL: 3 Q And do you stand by the -- a hundred percent 4 the results that are reported in the Woolen paper? 5 A Absolutely. 6 Can I just add: The point estimates are the 7 same for greater-than-10,000 exposures or greater than 8 30 times a month, and so when we were checking the 9 numbers, I think it was an oversight that we described 10 it as greater than 10,000 when, in fact, it was the 11 exact number greater than 30 times per month. 12 Q And when you said -- 13 THE REPORTER: I'm sorry. You trailed off. 14 THE WITNESS: The numbers that were extracted 15 are correct. The point estimate is the same for greater 16 than 10,000 or greater than 30 times per month, and the 17 description in Table 2 says greater-than-10,000-lifetime 18 exposures, but, indeed, reflects greater than 30 times 19 per month. You get the same point estimate, but the 20 data we abstracted were greater than 30 times per month. 21 BY MS. O'DELL: 22 Q You were asked a number of -- still on Woolen. 23 You were asked a number of studies -- "studies." Excuse 24 me -- a number of questions about the studies that 25 adjusted for patent versus nonpatent --	Page 210 1 study, the point estimate would clearly be higher than 2 we found. 3 MS. O'DELL: I have nothing further. Thank 4 you, Doctor. 5 I should ask -- 6 MR. HEGARTY: Thank you. I'll just state on 7 the record: We have some materials that need to be 8 copied and then provided as exhibits. That would 9 include the notebook pages, the three pages of notes, 10 and then the notebooks we marked. 11 Leigh, will you take possession of those and 12 make those copies, or do you want to do it in a 13 different way? 14 MS. O'DELL: I would like to talk to 15 Catherine, our court reporter, about taking possession 16 of the notebooks that will stay here in -- in San 17 Francisco. I'll take possession of the notes and make 18 sure they're scanned and provided and, of course, 19 returned to you, Dr. Smith-Bindman, but I will take 20 possession of those. 21 MR. HEGARTY: So you'll make arrangements with 22 the court reporter on how to get the notebooks copied 23 and -- 24 THE WITNESS: The notebooks will stay with the 25 court reporter?
Page 211 1 A Yes. 2 Q -- but didn't report separate data for both 3 patent and women with nonpatent -- 4 A Yes. 5 Q -- tubes. 6 And if, in fact, some of the women that were 7 included in the study -- studies had had hysterectomy or 8 had had tubaligation, cutting off the flow or exposure 9 of talcum powder applied perineally to the ovaries, 10 would that, in fact, have depressed the point estimate 11 for those individual studies? 12 MR. HEGARTY: Objection to the form. 13 THE WITNESS: The point estimates would be 14 even higher and further from the null if they were 15 limited to women who had patent tubes. 16 BY MS. O'DELL: 17 Q And so to the degree that counsel for Johnson 18 & Johnson has tried to draw a distinction, is that a 19 distinction, in your mind, that's meaningful? 20 MR. HEGARTY: Objection to the form. 21 THE WITNESS: I think had we had data to limit 22 to women with open tubes based on the study results that 23 almost uniformly showed the results were higher, there 24 was a greater chance of cancer in women who had open 25 tubes. Had we been able to extract that data from each	Page 213 1 MR. HEGARTY: -- included within the -- to the 2 exhibits -- included as an exhibit and then provided to 3 the parties? 4 MS. O'DELL: Yes. 5 MR. HEGARTY: Okay. 6 MS. O'DELL: Yes. I think -- I guess I want 7 to be clear: I'm taking responsibility for the notes 8 because some of the notes in Dr. Smith-Bindman's 9 notebooks were not related to talc. So I want to 10 oversee that process, but we're going to provide the 11 notebooks -- 12 MR. HEGARTY: Okay. 13 MS. O'DELL: -- to Golkow and the court 14 reporting service and let them handle -- 15 MR. HEGARTY: Okay. 16 MS. O'DELL: -- all of the details on that. 17 Thank you very much. 18 MR. HEGARTY: All right. I don't think I have 19 anything else. Thank you. 20 MS. O'DELL: We're off the record. 21 (TIME NOTED: 2:25 p.m.) 22 23 24 25